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ABSTRACT 
 
MARGARET ELIZABETH MCCORMICK: The adhesion molecule PECAM-1 directs 
endothelial nitric oxide synthase activity and cardiac function to regulate cardiovascular 
homeostasis 
(Under the direction of Ellie Tzima) 
 
 
The mammalian vascular system is integral to the regulation of homeostasis within 
an organism.  This system is composed of a vast network of blood vessels that transport 
oxygen and nutrients throughout the body.  Blood vessels are lined by endothelial cells 
(ECs) that provide an interface between circulating blood and the underlying tissue.  Based 
on their unique location, it is unsurprising that ECs are master regulators of numerous 
physiological processes.  ECs are equipped with receptors that interact with their 
surrounding environment. Among these molecules is Platelet Endothelial Cell Adhesion 
Molecule-1, or PECAM-1.  Since its identification in the early 1990s, PECAM-1 has gained 
increasing attention for its multi-faceted roles in vascular biology. In this dissertation, I 
describe two novel roles for PECAM-1 which advance our understanding for how this 
receptor regulates EC signaling and function.  
One of the most important cellular signaling molecules in the vasculature is nitric 
oxide (NO) generated by the enzyme endothelial nitric oxide synthase (eNOS). NO is 
required for vasodilation and maintenance of the endothelium.  Reduced NO production can 
lead to endothelial dysfunction, the first step in a host of diseases, including atherosclerosis 
(hardening of the arteries).  Previous studies have suggested a role for PECAM-1 in 
regulating eNOS activity and NO production. Here, I define a pathway by which PECAM-1 
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regulates the expression of a trafficking protein that influences eNOS localization and 
activity.   
 In the second half of my dissertation, I focus in vivo using wild type and PECAM-1-/- 
mice. Our lab has shown that PECAM-1-mediated signaling facilitates activation and 
expression of molecules that participate in cellular crosstalk.  Furthermore, it is well 
documented that cell crosstalk is central to proper cardiac function.  Therefore, we 
hypothesized that genetic deletion of PECAM-1 may have deleterious effects on heart 
function.  In agreement with this hypothesis, we are the first group to report that PECAM-1-/- 
mice display dilated cardiomyopathy. Work described in this dissertation defines the 
mechanism leading to these defects in function. Taken together, the work presented in this 
thesis further expands the evolving roles of PECAM-1 in cardiovascular biology and 
provides novel insight to its role in regulating organ function.  
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CHAPTER I. 
Introduction 
 
 
 
 
The vascular endothelium 
The vascular system plays a vital role in regulating homeostasis.  Defects in vascular 
function lead to the development of diseases such as atherosclerosis and coronary artery 
disease. In addition to transporting oxygen and nutrients, the vasculature is also 
fundamental for the delivery of important hormonal/neurohormonal signals that control organ 
system function. An illustration of this is the hormone vasopressin, which is released by the 
posterior pituitary and travels through the vasculature to the renal tubules to increased blood 
volume and ultimately blood pressure.  
William Harvey first described the presence of circulating blood in the early 1600s. 
Shortly after this observation, it was recognized that blood is separated from tissue by a 
series of vessels	  1.   It took over a century to realize that a thin layer of cells, termed 
endothelial cells (ECs), line the blood vessel wall.  Despite this observation, as recently as 
the 1960s, ECs were thought of simply as “the cellophane wrapper” of the vasculature	  2.  A 
tremendous amount of work done in the following decades revealed that ECs play a 
dynamic role in both physiology and pathology. ECs are found in every organ throughout the 
body and are specialized for their unique locations and varied function.  For instance, ECs in 
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the brain have tight junctions and a thick basement membrane to prevent the mixing of 
blood with cerebrospinal fluid.  Conversely, ECs of the glomerulus have specialized filtration 
slits to permit filtration of fluids and small molecules into the renal tubules.   
The endothelium is lined with receptors and adhesion molecules that provide a key 
interface between ECs and the extracellular environment.  These proteins also mediate 
intracellular signaling and facilitate complex interactions with neighboring cell types. EC 
input comes in many varieties, including circulating growth factors (vascular endothelial 
growth factor, VEGF), hormones (endothelin-1), metabolites (nitric oxide, NO) and 
mechanical forces (blood flow).  Due to their integral role, it is important to have a thorough 
understanding of how ECs are able to integrate information provided by their environment. 
 
PECAM-1 Structure and Function 
One important EC adhesion molecule is platelet endothelial cell adhesion molecule-1 
(PECAM-1).  In addition to being expressed on the surface of ECs, it is also found on 
platelets and leukocytes. PECAM-1 was initially identified for its role in leukocyte 
transendothelial migration, the process by which immune cells cross the vessel wall to 
underlying sites of inflammation	  3. More recently, it has been recognized as a multifaceted 
molecule in both endothelial and vascular biology.  
PECAM-1 is a 130-kD single-pass transmembrane protein and is concentrated at 
endothelial cell-cell junctions (Figure 1.1A). The extracellular domain contains 6 Ig-like 
domains (Figure 1.1B). Ig-like domains 1 and 2 facilitate homophilic interactions with 
PECAM-1 molecules on neighboring ECs	  4,	  5. The protein has a relatively short 118-amino 
acid cytoplasmic tail.  This region consists of 8 exons that can be alternatively spliced to 
generate various isoforms; however, the full-length protein is the most abundant	  6. Within the 
cytoplasmic domain are 2 immunoreceptor tyrosine-based inhibitory motifs domains (ITIMs).  
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When tyrosine residues Y663 and Y686 within these domains are phosphorylated, PECAM-1 
recruits Src-homology 2 (SH2) domain-containing proteins	  6.  This is critical for PECAM-1 
biology, as it allows the protein to participate in a number of important signaling pathways 
despite the lack of intrinsic kinase activity.  PECAM-1 becomes tyrosine phosphorylated in 
response to a number of signals, including homophilic binding and shear stress.  It has been 
previously shown that fluid shear stress (FSS) is a potent stimulus for PECAM-1 
phosphorylation by the Src-family kinase Fyn	  7,	  8.  PECAM-1 mediates a number of shear 
stress-responsive pathways, including the activation of phosphoinositide-3 kinase and Akt.  
Importantly, PECAM-1 null ECs display impaired responses to shear stress	  9.  
The PECAM-1-/- mouse was generated, in part, to address its role in leukocyte 
transendothelial migration (TEM)	  10.  Somewhat surprisingly, these animals were viable and 
had normal vasculogenesis despite previous studies implicating a role for PECAM-1 in 
angiogenesis	  11,	  12.  Initially, only minor defects in leukocyte TEM were identified in the 
PECAM-1-/- mouse. However, subsequent studies using other stress models, such as 
endotoxic induced-LPS shock, identified further defects in immunologic and angiogenic 
responses	  13-­‐15.  Additionally, our lab has demonstrated that PECAM-1 deficiency results in 
impaired flow-mediated vascular remodeling	  16. Furthermore, PECAM-1 null mice exhibit 
blunted arteriogenesis and reduced collateral remodeling due to deficits in shear stress-
induced endothelial nitric oxide synthase (eNOS) and nuclear factor kappa B (NF-κB) 
signaling	  17.  
 
eNOS and NO Signaling in endothelial cells 
Nitric Oxide (NO) is an important signaling molecule in the vascular system and 
regulates physiological activities including vascular tone, permeability of the endothelium, 
inflammation, cell proliferation, angiogenesis, and vascular remodeling	  18.  Within the 
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endothelium, eNOS catalyzes the formation of NO and L-citrulline through the oxidation of L-
arginine.  NO regulates vascular tone through activation of guanylyl cyclase and subsequent 
cGMP production in vascular smooth muscle cells (VSMCs). In this cell type, cGMP acts a 
second messenger to mediate relaxation and vasodilation. Numerous stimuli activate eNOS 
(via phosphorylation) to generate NO, including humoral factors, such as VEGF, bradykinin 
and estrogen, as well as mechanical forces such as shear stress, which is one of the most 
potent activators of eNOS	  19,	  20.  
The responsiveness of eNOS to diverse types of stimuli requires dynamic regulation 
of the enzyme. eNOS activity is regulated by several different mechanisms including protein-
protein interactions (Ca2+/Calmodulin (CaM), caveolin-1, and Hsp90); post-translational 
regulation (phosphorylation, acylation); cofactors and substrates (BH4); and subcellular 
localization (plasma membrane caveolae, Golgi, and cytosolic compartments)	  21,	  22. Basally, 
eNOS is kept inactive via association with the inhibitory protein caveolin-1 (Cav1), which 
typically occurs at the plasma membrane	  18.  Following stimulation, either through growth 
factors such as VEGF or shear stress, Ca2+/CaM is able to interact with eNOS.  This helps 
displace eNOS from binding Cav1 and subsequently activates the enzyme.  Additionally, 
FSS enhances the eNOS-Hsp90 interaction, thereby facilitating phosphorylation of Ser1179 
by Akt	  23,	  24. Phosphorylation of this serine residue plays a critical role in the early NO 
production in response to shear stress	  19. 
Subcellular localization is another important aspect of eNOS regulation.  There are 
three pools of eNOS located within the cell: at the perinuclear Golgi complex; at the plasma 
membrane; and a cytosolic compartment	  22.  eNOS is localized to the plasma membrane 
primarily in caveolae through acylation, including myristoylation and palmitoylation	  18. The 
plasma membrane pool of eNOS is highly responsive to increases in intracellular Ca2+ 
levels.  eNOS in the cis-Golgi is less responsive to Ca2+ and highly responsive to Akt-
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mediated activation	  25.  The proteins NOSIP (eNOS interacting protein)	  26 and NOSTRIN 
(eNOS traffic inducer)	  27 mediate trafficking of eNOS between the plasma membrane and 
Golgi complex.  Interestingly, the exact mechanisms that regulate this trafficking are not 
clearly established.    
Misregulation of eNOS signaling has profound consequences on the health of the 
blood vessel.  Endothelial dysfunction, present in a variety of pathologic conditions including 
atherosclerosis, is generally characterized by impaired NO production. It is therefore critical 
to characterize the mechanisms governing eNOS signaling to further understand how these 
processes contribute to vessel health and disease. eNOS-/- mice have been generated to 
address these important questions. Not surprisingly, these animals suffer from hypertension 
(through misregulated NO production), increased atherosclerotic lesions, and a heightened 
injury response	  28,	  29.  
In Chapter II, I describe a novel mechanism of basal eNOS regulation.  Previous 
studies have demonstrated a role for PECAM-1 in shear-induced eNOS activation. Here I 
show that PECAM-1 mediates basal eNOS activity through a pathway involving the eNOS 
trafficking protein NOSTRIN.  
 
NOSTRIN regulates eNOS trafficking and activity 
 One of the more recently described regulators of eNOS activity and localization is the 
cytoplasmic protein NOSTRIN.  This protein was discovered a decade ago in a yeast two-
hybrid screen using the oxygenase domain of human eNOS as bait	  27.  NOSTRIN is a 58-kD 
protein containing an N-terminal FCH region, a coiled-coil domain and C-terminal SH3 
domain (Figure 1.2).  The FCH region is followed by a coiled-coil stretch that composes the 
F-BAR domain, making it a member of the F-BAR (Fes/CIP4 homology and 
Bin/amphiphysin/Rvs) protein family.  These proteins are regulators of membrane and 
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cytoskeletal interactions	  30 and serve as adaptor proteins.  The SH3 domain is required for 
binding eNOS	  27 and the second coiled-coil domain facilitates oligomerization. NOSTRIN is 
expressed in highly vascularized tissues such as heart, lung and kidney	  27.  Much of the 
focus on NOSTRIN has been its role as a member of the complex eNOS trafficking 
machinery	  27.  It is able to independently bind both caveolin-1 and eNOS, forming a ternary 
complex important for eNOS localization	  31. Changes in NOSTRIN expression can alter 
eNOS activity and localization; when NOSTRIN is overexpressed, eNOS activity is 
significantly decreased	  31,	  32.   
More recent studies have revealed additional functions for NOSTRIN in endothelial 
cells.  In vivo studies using zebrafish have identified a novel role for NOSTRIN in mediating 
angiogenesis during development and in the adult	  33.  The authors demonstrate that 
NOSTRIN forms a complex with Rac1 and Sos1, important for FGFR1-mediated Rac1 
activation	  33.  In addition to the full-length protein a shortened isoform, NOSTRINβ, was 
recently described	  34.  Unlike NOSTRIN, this variant is primarily expressed in the nucleus 
and thought to regulate expression of the NOSTRIN gene. The importance of NOSTRIN in 
EC physiology and pathophysiology is currently the topic of ongoing investigation. 
 
Cell-cell crosstalk and implications in cell and organ function 
Cell-cell crosstalk, defined as communication through paracrine/autocrine factors 
released from one cell that affect the behavior and function of another cell, is an integral 
biological concept.  This phenomenon is essential both during development and is critical for 
maintaining homeostasis within the adult. Crosstalk occurs through a number of 
mechanisms, including release of soluble factors, differential expression of receptors and 
ligands, as well of direct cell contact	  35.  Importantly, cell crosstalk occurs in all tissues. 
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However, the research presented in this dissertation specifically focuses on the crosstalk 
between ECs and underlying cells.  
During development tissues release signaling molecules that influence migration, 
proliferation, and differentiation of constituent cells. For example, most tissues release the 
signaling protein VEGF that signals to ECs to induce the growth of new blood vessels.  This 
provides oxygen and nutrients to the newly forming tissue.  VEGF-mediated signaling is also 
necessary for the patterning and maintenance of the nascent blood vessels	  36.  Other 
examples of cytokines important in crosstalk during development include platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF), and bone morphogenic protein (BMP)	  
37.  Studies using genetic ablation of PDGF and its receptor PDGFR have demonstrated an 
important role for this signaling pathway in neural and vascular development	  38. In vascular 
development, PDGF is primarily secreted by ECs of the emerging vessel sprouts, while the 
receptor is expressed by pericytes and VSMCs. Here, EC-derived PDGF signaling 
stimulates both proliferation and migration of these neighboring cells to surround and 
stabilize developing blood vessels	  38.  
In the adult, cell crosstalk is essential for homeostasis. For instance, NO released 
from ECs signals to underlying VSMCs to regulate vessel tone. Misregulation of this 
signaling can lead to EC dysfunction and as mentioned previously, hypertension. 
Additionally, signaling from ECs to VSMCs can affect the growth and proliferation of VSMCs 
and their contractile properties. Cell crosstalk can also be facilitated through direct 
interaction of cells. For example, gap junctions, present in all cell types, mediate electrical 
and chemical communication. More specifically, within the heart, gap junctions are required 
for coordination of muscle contraction.  Targeted deletion of any number of connexins leads 
to cardiac phenotypes ranging from embryonic lethality to a tendency for arrythymias	  39.  
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The heart is an organ whose function relies heavily on the crosstalk between cell 
types; primarily the crosstalk between ECs and cardiomyocytes (CMs, heart muscle cells). 
ECs exist in close proximity to CMs, providing a microenvironment that facilitates EC-CM 
communication (Figure 1.3A-D). Cardiac ECs are thought to release a number of paracrine 
factors, including neuregulin-1 (NRG1), VEGF, and NO that influence CM function. 
Interestingly, crosstalk is reciprocated, as CMs release VEGF and angiopoietin to affect EC 
growth and function	  40.  Characterizing the regulation of these signaling pathways is 
physiologically relevant, as abnormal signaling can result in cardiac pathologies, such as 
cardiac hypertrophy.  
 
Cardiac function and dilated cardiomyopathy 
The heart is a fascinating organ; it beats continuously throughout our lifetime and is 
able to continuously adapt to changes in demand.  In order to function properly, it requires 
coordination of signaling pathways and electrical signals. Imbalance of either of these 
components can lead to dramatic and deleterious changes in heart structure or function. 
Diseases that are characterized by disruptions to structure or function are termed 
cardiomyopathies. Dilated cardiomyopathy is the most common cardiomyopathy worldwide 
and represents one of the most common causes of heart failure.  In this disorder, dilatation 
and impaired contraction of the ventricles develops and can lead to heart failure and sudden 
death.  Although myocardial injury, as well as abnormalities in the function and integrity of 
CMs, can lead to dilated cardiomyopathy, cardiac endothelial dysfunction has also been 
implicated in progression of the disease	  41.  In Chapter III, I describe a mechanism by which 
PECAM-1, expressed in ECs, is able to regulate signaling pathways in CMs that are 
important for proper coordination of contractility.  
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RESEARCH PRESENTED IN THIS DISSERTATION 
 
As described in the following chapters, the goals of this thesis are as follows (Figure 1.4): 
 
Chapter II. Determine the role of PECAM-1 in regulating basal eNOS activity  
eNOS plays an important role in vascular biology. Misregulation can lead to endothelial 
dysfunction and cardiovascular disease.  Previous studies have demonstrated a role for 
PECAM-1 in shear stress-induced eNOS activation.  However, my preliminary data showed 
that PECAM-1 knockout ECs have higher basal pSer1179eNOS compared to PECAM-1 
expressing cells. This observation suggests that PECAM-1 is not only required for shear-
induced eNOS activation but also regulates basal eNOS activity. In this chapter I will i) 
characterize the influence of PECAM-1 expression in basal eNOS activity and ii) determine 
the mechanism by which PECAM-1 regulates basal eNOS activity. I show that PECAM-1 
mediates basal eNOS activation, in part, by regulating the expression of the eNOS 
trafficking protein NOSTRIN. 
 
Chapter III. Determine the role of PECAM-1 in regulating cardiac function  
Previous studies have shown a requirement for PECAM-1 in regulating vascular function 
and remodeling.  Because the vascular system is important for cardiac function, I 
hypothesized that cardiac function would be impaired in PECAM-1-/- animals.  To address 
this possibility, we first performed echocardiography and found that the PECAM-1-/- hearts 
had impaired function relative to wild-type hearts. Using biochemical and ex vivo 
approaches, I show that this is due to misregulated signaling between ECs and CMs. In 
addition, by manipulating the hemodynamic environment of the heart, we implicate a role for 
PECAM-1 mechanosensing in regulation of cardiac function.  
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Chapter IV. Conclusions and Perspectives 
In this chapter, I discuss the significance of this work for the cardiovascular biology field and 
tie Chapter II and III together through similar themes and questions raised.  
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Figures 
Figure 1.1. Structure and localization of PECAM-1. 
 
A. Mouse endothelial cells stained for PECAM-1 (green), acetylated LDL (red) and nucleus 
(DAPI). PECAM-1 staining is concentrated as cell-cell junctions. The accumulation of 
acetylated LDL within these cells is a marker of ECs. B. Representative structure of 
PECAM-1. The protein has 6 extracellular Ig-like domains, a single pass transmembrane 
domain and a relatively short cytoplasmic tail which contains ITIM residues Y663 and Y686 
important for phosphorylation. 
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Figure 1.2. Multi-domain structure of NOSTRIN 
 
 
 
The cdc15/F-BAR domain, composed of an FCH and coiled-coil (cc1) domain, is important 
for directing the subcellular localization of NOSTRIN and particularly for membran binding. 
The C-terminal coiled-coil (cc2) domain is important for oligomerization of the protein and t 
he SH3 domain mediates interactions with binding partners such as eNOS and N-WASP. 
Image adapted from Ref. 32.  
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Figure 1.3. Intimate relationship between cardiac endothelial cells and 
cardiomyocytes. 
 
A. Schematic representation of the heart and arrangement of capillaries and cardiomyocytes 
in the heart.  Cardiomyocytes (CMs) are surrounded by approximately 4 capillaries (Cap). 
RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle. B. TRITC-lectin staining 
in the LV. Capillaries are labeled in red (arrowhead). Faint staining shows the outline of CMs 
(asterisk). C-D. TEM images of mouse heart. C. The capillary (Cap) is situated just next to 
the CM, and more importantly, the contractile apparatus of the CM. D. A magnified view of a 
Cap lined by EC (outlined) with a red blood cell (RBC) in the center of the capillary. 
	   14	  
Figure 1.4. Overview of research presented in this dissertation. 
 
	   15	  
 REFERENCES 
1. Fishman AP. Endothelium: a distributed organ of diverse capabilities. Ann N Y Acad Sci. 
1982; 401: 1-8. 
2. Florey. The endothelial cell. Br Med J. 1966; 2: 487-490. 
3. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial 
migration of leukocytes. J Exp Med. 1993; 178: 449-460. 
4. Sun J, Williams J, Yan HC, Amin KM, Albelda SM, DeLisser HM. Platelet endothelial cell 
adhesion molecule-1 (PECAM-1) homophilic adhesion is mediated by immunoglobulin-like 
domains 1 and 2 and depends on the cytoplasmic domain and the level of surface 
expression. J Biol Chem. 1996; 271: 18561-18570. 
5. Sun QH, DeLisser HM, Zukowski MM, Paddock C, Albelda SM, Newman PJ. Individually 
distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate 
receptor affinity. J Biol Chem. 1996; 271: 11090-11098. 
6. Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new 
roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol. 
2003; 23: 953-964. 
7. Osawa M, Masuda M, Kusano K, Fujiwara K. Evidence for a role of platelet endothelial 
cell adhesion molecule-1 in endothelial cell mechanosignal transduction: is it a 
mechanoresponsive molecule? J Cell Biol. 2002; 158: 773-785. 
8. Chiu YJ, McBeath E, Fujiwara K. Mechanotransduction in an extracted cell model: Fyn 
drives stretch- and flow-elicited PECAM-1 phosphorylation. J Cell Biol. 2008; 182: 753-763. 
9. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B, Cao G, 
DeLisser H, Schwartz MA. A mechanosensory complex that mediates the endothelial cell 
response to fluid shear stress. Nature. 2005; 437: 426-431. 
10. Duncan GS, Andrew DP, Takimoto H, Kaufman SA, Yoshida H, Spellberg J, Luis de la 
Pompa J, Elia A, Wakeham A, Karan-Tamir B, Muller WA, Senaldi G, Zukowski MM, Mak 
TW. Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion 
molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-
independent functions. J Immunol. 1999; 162: 3022-3030. 
11. Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-cell 
adhesion molecule. J Cell Biol. 1990; 110: 1227-1237. 
12. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, 
Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. Involvement of 
endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997; 151: 671-677. 
	   16	  
13. Carrithers M, Tandon S, Canosa S, Michaud M, Graesser D, Madri JA. Enhanced 
susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am 
J Pathol. 2005; 166: 185-196. 
14. Schenkel AR, Chew TW, Muller WA. Platelet endothelial cell adhesion molecule 
deficiency or blockade significantly reduces leukocyte emigration in a majority of mouse 
strains. J Immunol. 2004; 173: 6403-6408. 
15. Solowiej A, Biswas P, Graesser D, Madri JA. Lack of platelet endothelial cell adhesion 
molecule-1 attenuates foreign body inflammation because of decreased angiogenesis. Am J 
Pathol. 2003; 162: 953-962. 
16. Chen Z, Tzima E. PECAM-1 is necessary for flow-induced vascular remodeling. 
Arterioscler Thromb Vasc Biol. 2009; 29: 1067-1073. 
17. Chen Z, Rubin J, Tzima E. Role of PECAM-1 in arteriogenesis and specification of 
preexisting collaterals. Circ Res. 2010; 107: 1355-1363. 
18. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res. 
2007; 75: 247-260. 
19. Boo YC, Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of 
protein kinases. Am J Physiol Cell Physiol. 2003; 285: C499-508. 
20. Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of 
endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996; 79: 984-
991. 
21. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 
2009; . 
22. Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ, Iwakiri Y, Sessa 
WC. Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi 
complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for 
nitric oxide release. J Biol Chem. 2004; 279: 30349-30357. 
23. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa 
WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998; 392: 
821-824. 
24. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc 
Natl Acad Sci U S A. 2000; 97: 10832-10837. 
25. Zhang Q, Church JE, Jagnandan D, Catravas JD, Sessa WC, Fulton D. Functional 
relevance of Golgi- and plasma membrane-localized endothelial NO synthase in 
reconstituted endothelial cells. Arterioscler Thromb Vasc Biol. 2006; 26: 1015-1021. 
26. Dedio J, Konig P, Wohlfart P, Schroeder C, Kummer W, Muller-Esterl W. NOSIP, a novel 
modulator of endothelial nitric oxide synthase activity. FASEB J. 2001; 15: 79-89. 
	   17	  
27. Zimmermann K, Opitz N, Dedio J, Renne C, Muller-Esterl W, Oess S. NOSTRIN: a 
protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide 
synthase. Proc Natl Acad Sci U S A. 2002; 99: 17167-17172. 
28. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction 
of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response 
to injury in mice. J Clin Invest. 1998; 101: 1225-1232. 
29. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, 
Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart 
disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. 
Circulation. 2001; 104: 448-454. 
30. Cooper KM, Bennin DA, Huttenlocher A. The PCH family member proline-serine-
threonine phosphatase-interacting protein 1 targets to the leukocyte uropod and regulates 
directed cell migration. Mol Biol Cell. 2008; 19: 3180-3191. 
31. Schilling K, Opitz N, Wiesenthal A, Oess S, Tikkanen R, Muller-Esterl W, Icking A. 
Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveolin-1 
and NOSTRIN. Mol Biol Cell. 2006; 17: 3870-3880. 
32. Icking A, Matt S, Opitz N, Wiesenthal A, Muller-Esterl W, Schilling K. NOSTRIN 
functions as a homotrimeric adaptor protein facilitating internalization of eNOS. J Cell Sci. 
2005; 118: 5059-5069. 
33. Kovacevic I, Hu J, Siehoff-Icking A, Opitz N, Griffin A, Perkins AC, Munn AL, Muller-
Esterl W, Popp R, Fleming I, Jungblut B, Hoffmeister M, Oess S. The F-BAR protein 
NOSTRIN participates in FGF signal transduction and vascular development. EMBO J. 
2012; 31: 3309-3322. 
34. Wiesenthal A, Hoffmeister M, Siddique M, Kovacevic I, Oess S, Muller-Esterl W, Siehoff-
Icking A. NOSTRINbeta--a shortened NOSTRIN variant with a role in transcriptional 
regulation. Traffic. 2009; 10: 26-34. 
35. Davies PF. Vascular cell interactions with special reference to the pathogenesis of 
atherosclerosis. Lab Invest. 1986; 55: 5-24. 
36. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their 
inhibitors. Nat Med. 1999; 5: 1359-1364. 
37. Zerwes HG, Risau W. Polarized secretion of a platelet-derived growth factor-like 
chemotactic factor by endothelial cells in vitro. J Cell Biol. 1987; 105: 2037-2041. 
38. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003; 130: 
4769-4784. 
39. Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res. 
2004; 62: 228-232. 
	   18	  
40. Tirziu D, Giordano FJ, Simons M. Cell communications in the heart. Circulation. 2010; 
122: 928-937. 
41. Roura S, Bayes-Genis A. Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat 
Rev Cardiol. 2009; 6: 590-598.
  
 
 
CHAPTER II. 
PECAM-1 regulates eNOS activity and localization through STAT3-dependent 
NOSTRIN expression. 
 
 
 
 
Overview 
Objective: Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is an 
important regulator of cardiovascular physiology and pathology. eNOS is activated by 
numerous stimuli and its activity is tightly regulated. Platelet-endothelial cell adhesion 
molecule-1 (PECAM-1) has been implicated in regulating eNOS activity in response to shear 
stress. The goal of the current study is to determine the role of PECAM-1 in the regulation of 
basal eNOS activity. 
Methods and Results: We demonstrate that PECAM-1 knockout ECs have increased basal 
eNOS activity and NO production. Mechanistically, increased eNOS activity is associated 
with a decrease in the inhibitory interaction of eNOS with caveolin-1; impaired subcellular 
localization of eNOS; and decreased NOSTRIN expression in the absence of PECAM-1. 
Furthermore, we demonstrate that blunted STAT3 activation in the absence of PECAM-1 
results in decreased NOSTRIN expression via direct binding of STAT3 to the NOSTRIN 
promoter.  
Conclusions: Taken together, our results reveal an elegant mechanism of eNOS regulation 
by PECAM-1 through STAT3-mediated transcriptional control of NOSTRIN. 
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Introduction 
The production of NO is critical for cardiovascular homeostasis as NO regulates 
many fundamental cellular processes, including regulation of vessel tone, cell proliferation, 
and angiogenesis	  1. In the vascular endothelium, NO is synthesized from L-arginine by the 
constitutively expressed endothelial nitric oxide synthase (eNOS or NOS3) enzyme. eNOS 
function is critical, as genetic deletion of eNOS results in increased blood pressure	  2,	  3, 
impaired angiogenesis, abnormal vascular remodeling, and accelerated atherosclerosis	  4. 
Numerous stimuli promote the activation of eNOS through phosphorylation of serine residue 
1179, leading to NO production.  In this regard, it has been shown that the cell adhesion 
molecule PECAM-1 regulates eNOS activation in vitro and in vivo, possibly via a direct 
interaction between PECAM-1 and eNOS	  5,	  6.  However, the specifics of this interaction are 
not known.  
eNOS is regulated by multiple interdependent control mechanisms; including post-
translational lipid modifications, phosphorylation, localization and protein-protein interactions	  
7-­‐9. Together, these regulatory mechanisms ensure proper responses to diverse stimuli.  
eNOS is basally repressed through its interaction with an integral membrane protein, 
caveolin-1, which inhibits NO production	  10. In addition, studies show that trafficking and 
proper subcellular localization of eNOS are also critical for regulation of its activity	  10,	  11.  
There are three pools of eNOS located within the cell: (1) the perinuclear Golgi complex; (2) 
the plasma membrane (primarily in caveolae); and (3) a cytosolic compartment.  It is 
increasingly appreciated that eNOS can traffic between these compartments and that 
subcellular targeting can affect NO production in response to various stimuli	  12,	  13. Recent 
studies have identified several eNOS trafficking proteins including NOSIP (eNOS interacting 
protein)	  14 and NOSTRIN (eNOS traffic inducer)	  12. NOSTRIN is expressed in ECs both in 
vitro and in vivo	  12,	  15 and regulates eNOS trafficking and localization	  12,	  15,	  16. Although 
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proteins that influence localization have been identified, the mechanisms that control eNOS 
trafficking and the (patho)physiologic consequences are not fully understood. 
Here, we investigate the role of PECAM-1 in the regulation of basal eNOS activity. 
We reveal an elegant mechanism of eNOS regulation through transcriptional control of 
NOSTRIN expression. 
 
Materials and Methods 
Animals 
PECAM-1–/– C57BL/6 mice were kindly provided by Dr P. Newman (Blood Research 
Institute, BloodCenter of Wisconsin, Milwaukee) and eNOS-GFP transgenic mice were 
kindly provided by Rini de Crom (Erasmus University Medical Center, Rotterdam, The 
Netherlands). All mice were bred in house and used in accordance with the guidelines of the 
National Institute of Health and the care and use of laboratory animals (approved by the 
Institutional Animal Care and Use Committees of the University of North Carolina at Chapel 
Hill). Mice aged 12-16 weeks were used for all experiments.   
 
Cell culture and Reagents 
PECAM-1 knockout (PE-KO) cells and cells reconstituted with murine full-length PECAM-1 
(PE-RC) we prepared as described	  17.  HUVECs (Lonza) were grown in M199 media 
supplemented with EGM2 bullet kit. Cucurbitacin I was purchased from Tocris Bioscience 
(Ellsville, Missouri).  Antibodies to phospho-Ser1179 eNOS and phospho-Tyr STAT3 were 
from Cell Signaling (Danvers, MA). Anti-GM130 was from BD Biosciences (Transduction, 
San Diego) and total STAT3 (Santa Cruz, CA) and total GAPDH from Millipore (Temecula, 
CA).    
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Immunoprecipitation and Western Blotting  
Cells were harvested in lysis buffer as previously described	  18. Lysates were assayed by 
Western blot.  For immunoprecipitation, cells were harvested in OG buffer plus protease 
inhibitors	  19.  Equivalent volumes of lysate were pre-cleared with Protein A/G Plus-Agarose 
beads (Santa Cruz Biotechnology, Inc) for 1 hour at 4°C.  Supernatants were then incubated 
with Protein A/G beads previously conjugated with anti-rabbit caveolin-1 (BD Transduction).  
Complexes were washed three times OG buffer and then assayed by Western blot.  
 
Immunofluorescence 
PE-RC and PE-KO cells were fixed and permeabilized in 3.7% formaldehyde with 0.2% 
Triton X-100 for 30 minutes at 37°C then blocked in 1% BSA in PBS for 30 minutes at 37°C.  
Cells were stained for total eNOS (BD Transduction) and Alexa488-conjugated Giantin 
(Covance).  Images were taken using either the Zeiss LSM5 Pascal Confocal microscope 
using a 63X oil lens.  Co-localization was determined using ImageJ and the Mander’s 
colocalization coefficient	  20.  Aorta en face preparations we prepared as previously 
described	  21.  En face preparations were evaluated with a Zeiss LSM5 Pascal microscope. 
 
Cellular Fractionation 
Confluent PE-RC and PE-KO cells were fractionated as previously described	  22.  The 
samples (25ul) were run on 4-12% SDS-PAGE gels then transferred to nitrocellulose 
membrane for Western blot analysis.  Membranes were probed with total eNOS, GM130 as 
Golgi marker and caveolin-1 as the plasma membrane marker.  
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In vitro and in vivo NO Measurements 
Cells were serum-starved for 24 hours then treated with either 100mmol/L L-Name, 1µmol/L 
ionomycin or L-Name plus ionomycin.  Media NO levels were evaluated using the Griess 
reagent (NO Assay kit, R&D Systems).  PECAM-1 +/+ and -/- animals were anesthetized using 
intraperitoneal (IP) injections of ketamine (100mg/kg) and xylazine (15mg/kg) and injected 
with 100U heparin.  Plasma was isolated for NO measurements, which were performed 
using a NO analyzer (Sievers Instruments, Boulder, CO) as previously described	  23. 
 
RNA Isolation and Quantitative PCR 
Total RNA was isolated from a confluent cell monolayer using the TRIzol reagent 
(Invitrogen) and first-strand cDNA was transcribed using random primers and SuperScript II 
Reverse Transcriptase (Invitrogen). Real-time quantitative PCR was performed using 
ABsolute SYBR Green ROX mix (Thermo Scientific). Relative levels of gene expression 
were normalized to mouse 18s expression using the comparative Ct method. 
 
Chromatin Immunoprecipitation (ChIP) Assays 
Chromatin immunoprecipitation was performed using the fast ChIP method described by 
Nelson et al	  24 using a rabbit anti-STAT3 K15 antibody (Santa Cruz Biotechnology, Inc). 
Quantitative PCR was performed using primers specific for the NOSTRIN promoter. 
 
Quantification and Statistical Analysis 
Band intensity of immunoblots was quantified using the ImageJ program. Each experimental 
group was analyzed using single factor analysis of variance. P-values were obtained by 
performing two-tailed Student's t test using Excel (Microsoft). Statistical significance was 
defined as P<0.05. 
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Results 
PECAM-1 regulates basal eNOS activity 
Previous studies suggest a requirement for PECAM-1 in shear-induced eNOS 
activation	  10,	  25,	  26. Our own results are in agreement with these observations (data not 
shown).  Unexpectedly, our data revealed increased levels of phosphorylated eNOS in 
PECAM-1 knockout (PE-KO) cells compared to PECAM-1 expressing cells (PE-RC) (Figure 
2.1A).  PECAM-1 deletion, however, does not affect total eNOS expression	  25. To evaluate 
the functional consequences of increased basal eNOS phosphorylation in the PE-KO cells, 
we measured NO production. As shown in Figure 2.1B, there is a 3-fold increase in basal 
NO production in PE-KO cells compared to PE-RC cells.  Stimulation with ionomycin 
increased NO production in both cell types, whereas L-NAME inhibited the production of 
NO. To determine if these observations are corroborated in whole animals, we measured 
NO levels from plasma.  Indeed, plasma NO levels were higher in PECAM-1-/- compared to 
PECAM-1+/+ animals (Figure 2.1C).   
To further investigate the role of PECAM-1 in regulation of basal eNOS 
phosphorylation, we used siRNA to knockdown PECAM-1 expression in human umbilical 
vein endothelial cells (HUVECs). The degree of knockdown was assessed by Western blot 
(Supplemental Figure 2.1A).  Interestingly, we observed an increase in both basal eNOS 
phosphorylation (Supplemental Figure 2.1B) and NO production (Supplemental Figure 2.1C) 
in PECAM-1-siRNA infected ECs compared to control siRNA cells. Together, these data 
suggest that absence of PECAM-1 results in higher basal eNOS activity and NO production. 
 
Differential association of eNOS and caveolin-1 in the absence of PECAM-1 
We next wanted to address the mechanism(s) responsible for the increased basal 
eNOS activity in the absence of PECAM-1.  To determine if PECAM-1 affects the interaction 
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between eNOS and known regulatory proteins we performed co-immunoprecipitation 
assays.  The caveolar scaffolding protein, caveolin-1, has been shown to regulate eNOS 
activity, primarily as an inhibitor of basal enzyme function	  10,	  19,	  27. Caveolin-1 is able to bind 
eNOS and block the calmodulin-binding site important for enzyme activation	  28.  To 
determine if PECAM-1 affects the association of eNOS with caveolin-1, we performed co-
immunoprecipitation assays.  As shown in Figure 2.2, there was a decrease in basal eNOS-
caveolin-1 association in the PE-KO cells compared to the PE-RC cells.  Additionally, we 
see a decrease in the colocalization of eNOS and caveolin-1 by confocal microscopy, 
supporting our immunoprecipitation data (data not shown). These data suggest that 
PECAM-1 may regulate basal eNOS activity by promoting the association of eNOS with 
caveolin-1.   
 
Role of PECAM-1 in eNOS localization/trafficking 
Subcellular localization of eNOS influences its activation	  11,	  13,	  23,	  29.  To determine if 
PECAM-1 influences eNOS localization, we performed double-labeling immunofluorescence 
confocal microscopy in PE-RC and PE-KO cells.  Cells were stained for total eNOS and 
giantin, a membrane-inserted component of the cis- and medial-Golgi complex.  In PECAM-
1 expressing cells, eNOS is found at both the perinuclear/Golgi complex and the plasma 
membrane (PM) (Figure 2.3A), consistent with the localization described in blood vessels in 
vivo	  113. In contrast, in cells that lack PECAM-1, eNOS is redistributed away from the 
perinuclear region (Figure 2.3A). Indeed, quantitative colocalization analysis (Mander’s 
colocalization coefficient) showed decreased colocalization of eNOS with giantin in the 
absence of PECAM-1 (Figure 2.3A). Together, these data suggest that PECAM-1 influences 
the subcellular localization of eNOS. 
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To further support our in vitro findings, we isolated aortas from PECAM-1+/+ and -/- 
mice expressing an eNOS-GFP fusion protein.  The aortas were stained en face for giantin 
and visualized using confocal microscopy (Figure 2.3B). Similar to the PE-KO cells, 
quantitative colocalization analysis revealed a significant redistribution of eNOS away from 
the Golgi complex in the PECAM-1-/- aortas.  
As a complementary approach, we utilized sodium carbonate extraction of cells 
followed by a discontinuous sucrose gradient. In this procedure, cholesterol-rich 
microdomains, including lipid rafts and caveolae, float as buoyant membranes at the 5–30% 
sucrose interface (fractions 3-4), whereas soluble proteins and heavy membranes remain at 
the bottom of the gradient (fractions 9–11). In all gradients, the distribution of caveolin-1 and 
GM130, a Golgi marker, were examined to confirm adequate separation of the fractions 
(Figure 2.3C). In PECAM-1-expressing ECs, eNOS distributed primarily into two distinct 
pools: light membranes highly enriched in caveolin-1 and heavy membranes enriched in 
GM130. In PE-KO cells, eNOS is also distributed into two pools. However, we noticed a 
significant redistribution of eNOS out of the Golgi-enriched fractions (fractions 10-11).  
These observations are consistent with the immunofluorescence data described above. 
Notably, PE-KO cells have increased eNOS activity and NO levels despite increased 
expression levels of the negative regulator caveolin-1 (not shown).  
 
PECAM-1 mediates STAT3-dependent NOSTRIN expression in ECs  
eNOS localization is a dynamic and well-coordinated process, mediated by a number 
of players including dynamin-2 and NOSTRIN	  9.  To determine if PECAM-1 mediates eNOS 
localization through NOSTRIN, we measured NOSTRIN protein expression in PE-RC and 
PE-KO cells.  Unexpectedly, we observed a significant decrease in NOSTRIN protein 
expression in PE-KO cells (Figure 2.4A). Reduced NOSTRIN expression in PE-KO cells 
could be due to either increased protein degradation or a reduction in mRNA levels.  To 
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distinguish between these possible mechanisms, we first measured ubiquitination of 
NOSTRIN but did not observe a difference between the PE-RC and PE-KO cells (data not 
shown).  Next, we used quantitative real-time PCR to determine the effect of PECAM-1 
deletion on NOSTRIN mRNA levels.  Our data demonstrate that NOSTRIN mRNA is 
significantly decreased in the absence of PECAM-1 (Figure 2.4B).   
We next addressed the mechanism by which PECAM-1 affects NOSTRIN protein 
expression.  It has previously been shown that the cytoplasmic tail of PECAM-1 is able to 
function as a scaffold for numerous signaling pathways, including signal transducers and 
activators of transcription (STAT) protein family members STAT5 and STAT3	  30,	  31.  
Additionally, ECs isolated from PECAM-1-/- mice have reduced STAT3 phosphorylation	  31. 
We asked whether the reduced levels of active STAT3 in the PECAM-1 knockout might 
result in decreased NOSTRIN expression.  To determine if STAT3 phosphorylation is 
reduced in cells that lack PECAM-1, we probed PE-KO cell extracts for total STAT3 and 
phospho-STAT3.  Importantly, our data are in agreement with previous reports showing that 
phospho-STAT3 levels are lower in the absence of PECAM-1 (Figure 2.5A).  To determine if 
STAT3 activity affects NOSTRIN expression, we treated the PECAM-1 expressing ECs with 
cucurbitacin, a selective inhibitor of STAT3/JAK signaling, and assayed for changes in 
NOSTRIN expression by Western blot and quantitative real-time PCR. Cucurbitacin 
treatment results in a dose-dependent decrease in both NOSTRIN protein expression 
(Figure 2.5B) and mRNA levels (Figure 2.5C). These results suggest that PECAM-1 
mediates STAT3-induced NOSTRIN expression, which, in turn, regulates eNOS localization.  
 
Binding of STAT3 to the NOSTRIN promoter in endothelial cells  
Analysis of the NOSTRIN promoter revealed several putative STAT3 binding sites 
(Supplemental Table 2.1). STAT family members bind to a conserved sequence of TT and 
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AA duplicates typically separated by 5 bases. In addition to binding TT(N5)AA nanomers, 
STAT3 is also able to bind octomers and decamers	  32,	  33.  We next investigated the 
possibility that STAT3 directly binds to the NOSTRIN promoter to modulate mRNA 
expression by chromatin immunoprecipitation (ChIP) assays with STAT3 antibodies.  
Immunoprecipitation of the chromatin lysates was followed by PCR with NOSTRIN promoter 
primers; NOSTRIN exon 10 primers served as a control. ChIP assays show that STAT3 
binds to the NOSTRIN promoter region, but not the NOSTRIN coding region (Figure 2.5D).  
Together, these data suggest that STAT3 may regulate NOSTRIN mRNA levels by 
specifically binding to the NOSTRIN promoter.  
 
Discussion 
Understanding the mechanisms that regulate NO production in the endothelium can 
provide important insight into processes that initiate endothelial dysfunction and lead to the 
development of atherosclerosis.  NO production is dynamically regulated by a number of 
humoral and mechanical factors. In this study, we investigated PECAM-1 regulation of basal 
eNOS activity. An unexpected finding of this study was the increased basal eNOS activity 
and NO production in PE-KO cells as well as PECAM-1-/- mice.  An attractive hypothesis to 
explain the basal regulation of eNOS by PECAM-1 is their reported physical association. 
However, reports of this interaction have been highly conflicting. One group showed that 
shear stress induces a transient increase in the association of PECAM-1 and eNOS	  6, while 
other studies have shown just the opposite	  5. Our own results suggest only a weak basal 
association of eNOS and PECAM-1 in static ECs (data not shown).  In addition, ultra-
structural and biochemical analyses suggest that eNOS resides within caveolae	  10,	  34, 
whereas PECAM-1 is found at a membrane network just below the plasmalemma at the cell 
borders that is distinct from caveolae	  35. Furthermore, studies in HUVECs have shown no 
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colocalization between PECAM-1 and caveolin-1 and that these two proteins do not co-
migrate on sucrose gels	  35. The lack of physical association between eNOS and PECAM-1 
led us to investigate differences in eNOS protein interactions and localization as possible 
mechanisms of regulation.  
It is well recognized that correct subcellular targeting of eNOS is critical for proper 
regulation of its activity and NO bioavailability; thus, tight control of eNOS targeting to 
different compartments appears to be essential. In this regard, our data point towards a 
requirement for tightly regulated levels of NOSTRIN expression within ECs. Overexpression 
of NOSTRIN can promote the translocation of eNOS from the plasma membrane to 
intracellular vesicles, with a concomitant reduction in eNOS enzyme activity	  12. Conversely, 
decreased NOSTRIN expression also influences eNOS subcellular localization and may 
contribute to the increased NO levels observed in the PECAM-1 knockout. Interestingly, 
overexpression of the eNOS-binding partner, caveolin-1, leads to accelerated 
atherosclerosis formation in mice, partially through reduced NO production	  36; while 
persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary 
hypertension	  37. Thus, tight regulation of eNOS regulatory protein levels, including NOSTRIN 
and caveolin-1 expression, is required for proper eNOS function.  
Here, we present exciting data to support a novel mechanism of eNOS regulation by 
PECAM-1. Our current working model is summarized in Figure 2.6.  The cytoplasmic tail of 
PECAM-1 acts as a scaffold for STAT3 and mediates its activation. A possible candidate for 
the activation of STAT3 are the Src-family kinases, as Src-mediated STAT activation has 
been previously reported	  38,	  39.  Following activation, STAT3 dimerizes and translocates into 
the nucleus where it modulates expression of gene targets, including NOSTRIN.  Once 
expressed, NOSTRIN facilitates eNOS trafficking and its correct subcellular localization.  It is 
possible that the reduced NOSTRIN levels account for the difference in eNOS-caveolin-1 
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association, however this could be due to other undetermined mechanisms. Of note, it has 
been reported that eNOS, caveolin-1 and NOSTRIN form a ternary complex to facilitate 
eNOS translocation	  16. Additionally, our data are consistent with the hypothesis that 
NOSTRIN might serve to stabilize the inhibitory effect of caveolin-1 on eNOS	  16.   
The signaling pathway identified here relates to the regulation of basal eNOS activity 
via PECAM-1. However, PECAM-1 is also known to regulate eNOS activation in response to 
the physiologic stimulus of shear stress	  5,	  6,	  25,	  40. PE-KO cells are unable to activate eNOS in 
response to shear stress, yet they activate eNOS in response to ionomycin, indicating a 
specific requirement for PECAM-1 in flow-induced eNOS activation (Figure 2.1B and 
Supplemental Figure 2.2). It is worth noting here that PECAM-1 is also required for flow-
induced activation of Akt and Src, two important upstream mediators of eNOS activity	  25,	  40. 
The role of shear stress in NOSTRIN-mediated eNOS regulation is currently under 
investigation.   
Blood flow and the NO signaling pathway are both known modulators of 
cardiovascular development and physiology.  Two recent studies have provided compelling 
evidence for an evolutionarily conserved, shear stress- and NO-mediated pathway that also 
regulates hematopoiesis	  41-­‐43. PECAM-1 is thought to be involved in flow mechanosensing, 
based on in vitro and in vivo experiments showing PECAM-1-dependent activation of flow-
mediated intracellular signaling pathways and vascular remodeling	  6,	  44,	  45. Interestingly, 
PECAM-1 is required for NO-mediated dilation in response to shear stress in isolated 
skeletal muscle arterioles	  40 as well as in the mouse coronary circulation	  46, thus 
underscoring the importance of both PECAM-1 and NO in flow-mediated remodeling. 
Previous studies have also identified the importance of eNOS in flow-mediated remodeling	  
47. We now reveal a sophisticated dual mode of eNOS regulation by PECAM-1 in vitro; while 
PECAM-1-/- ECs are unable to activate eNOS in response to shear stress, their basal eNOS 
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activity and NO levels are, paradoxically, increased through STAT3-mediated transcriptional 
control of NOSTRIN. Our findings underscore the dynamic regulation of proteins integral to 
the regulation of vascular homeostasis. 
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Figures 
 
Figure 2.1. Basal eNOS phosphorylation and NO production in the PECAM-1 KO.   
 
A,  PE-KO cells have increased basal peNOS compared to PE-RC (n=6, *P<0.005). B, PE-
RC and PE-KO cells were treated with 1mmol/L L-Name or 1µmol/L ionomycin and NO 
levels measured (n=3, *P<0.01 vs PE-RC basal). C, Plasma levels of NO from PECAM-1+/+ 
and -/- mice were assayed as described.  (n=7 mice;*P<0.05 vs PECAM-1 +/+). 
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Figure 2.2. Differential association of the negative eNOS-binding partner, caveolin-1, 
in the absence of PECAM-1.   
 
PE-RC and PE-KO cells were immunoprecipitated using an antibody against Cav1.  
Western blots were performed for total eNOS and Cav1. Quantitation is shown on the right 
(n=6; *P<0.001 vs PE-RC).  
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Figure 2.3. PECAM-1 regulates eNOS subcellular localization.  
 
A, PE-RC and PE-KO cells stained for total eNOS (red) and Giantin (green).  Colocalization 
was determined using the thresholded Mander’s coefficient (n=4, 25 cells/experiment; 
*P<0.05). B, En face aortas from eNOS-GFP/PECAM-1 +/+ or -/- mice stained for Giantin 
(red) (50 cells/genotype; *P<0.05).  C, Subcellular fractionation of PE-RC and PE-KO cells.  
Fractions were immunoblotted for total eNOS, GM130 and Cav-1 (n=3, *P<0.05). Bar = 
5µm. 
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Figure 2.4. Reduced NOSTRIN expression in ECs lacking PECAM-1. 
 
A, Levels of NOSTRIN protein were measured in PE-RC and PE-KO cells by Western Blot. 
GAPDH was measured for loading (n=4, *P<0.001 vs PE-RC). B, Real-time PCR analysis 
revealed decreased NOSTRIN mRNA levels in PE-KO cells (n=5, *P<0.001 vs 
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Figure 2.5.  PECAM-1 regulates NOSTRIN in a STAT3-dependent manner.  
 
A, Western blot for phosphorylated STAT3 in PE-RC and PE-KO cells.  Quantitation shown 
on right (n=3, P<0.01 vs PE-RC). B, PE-RC and PE-KO cells treated for 24 hours with 0.5, 5 
and 20µmol/L cucurbitacin then lysed and NOSTRIN protein expression determined by 
Western Blot. Values normalized to GAPDH (n=3, *P<0.05). C, Real-time PCR analysis of 
NOSTRIN mRNA expression in PE-RC cells treated for 12hrs with cucurbitacin. (n=3, 
*P<0.001). D. ChIP on PE-RC cells for STAT3 binding to NOSTRIN promoter region. 
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Figure 2.6. Model of PECAM-1-mediated NOSTRIN expression and eNOS trafficking.  
 
 
The cytoplasmic tail of PECAM-1 acts as a scaffold for STAT3 binding. Following activation, 
STAT3 translocates to the nucleus where it regulates NOSTRIN mRNA expression. 
NOSTRIN protein is then able to bind eNOS and regulate its trafficking and localization with 
the cell.  
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Supplemental Material 
Cellular Fractionation 
Cells were washed twice with cold PBS then scraped into 2 ml of PBS and centrifuged at 
1000 rpm for 3 minutes to pellet cells.  The PBS was removed and the cells were 
resuspended in 750 µl of 500mmol/L sodium carbonate, pH 11.  The cells were dounce-
homogenized (25 strokes) on ice and sonicated at 50% power with 5 10-second bursts.  The 
homogenate was adjusted to 42.5% sucrose using a 58% sucrose solution prepared in MBS 
(25mmol/L MES, pH 6.5, 0.15mol/L NaCl).  500 µl of homogenate was placed at the bottom 
of an ultracentrifuge tube then 1 ml of 30% sucrose was added followed by 600ul of 5% 
sucrose in MBS.  The samples were centrifuged at 48,000 rpm for 3 hours at 4°C in using 
the SW50 Rotor (Beckman). Aliquots of 200ul were taken starting from the top (for a total of 
12 samples) and added to 50ul 10X LSB.  The samples (25ul) were run on 4-12% SDS-
PAGE gels then transferred to nitrocellulose membrane for Western blot analysis.  
Membranes were probed with total eNOS, GM130 as Golgi marker and caveolin-1 as the 
plasma membrane marker. 
 
En Face Staining 
Aortas were perfusion-fixed and dissected out under a dissection microscope. The aorta 
was trimmed of fat and excess tissue then cut longitudinally and permeabilized for 3 hours in 
0.2% Tx100. Tissue was blocked in PBT (1% BSA, 0.1% Tween-20 in PBS) overnight at 
4°C.  Tissues were then placed on slides with the endothelium facing up, covered with 
Vectashield plus DAPI and mounted. Samples were incubated for 120 minutes at room 
temperature in Giantin antibody (1:50, Covance), then incubated for 60 minutes in 
secondary antibody at room temperature. 
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RNA Isolation and Quantitative PCR 
Total RNA was isolated from a confluent cell monolayer using the TRIzol reagent 
(Invitrogen) and DNAse treatment was performed using DNA-free (Ambion). First-strand 
cDNA was transcribed using random primers and SuperScript II Reverse Transcriptase 
(Invitrogen). Real-time quantitative PCR was performed using ABsolute SYBR Green ROX 
mix (Thermo Scientific). Relative levels of gene expression were normalized to mouse 18s 
expression using the comparative Ct method. Primer sequences are listed in supplemental 
Table 1. 
Chromatin Immunoprecipitation 
Chromatin-containing lysates were incubated with rabbit anti-STAT3 K15 (Santa Cruz 
Biotechnology, Inc) for 30 minutes at 4°C in an ultrasonicator bath. DNA-protein complexes 
were precipitated using Protein A/G agarose beads and treated with proteinase K.  DNA 
samples were extracted using 10% wt/vol Chelex (Bio-Rad) and PCR amplified using 
primers specific for the NOSTRIN promoter (sequences listed in Table 1). 
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Supplemental Figures  
Supplementary Figure 2.1. PECAM-1 knockdown in HUVECs.  
 
A, HUVECs were treated with lentivirus expressing PECAM-1 siRNA (PECO2) or a non-
specific control (NSC).  Levels of knockdown were assayed by Western blot for PECAM-1 
and tubulin. B, Lentivirus-treated HUVECs were assayed for pSer1179eNOS by Western 
blot (n=3; P<0.05 vs HUVEC NSC). C, NO levels in PECAM-1 knockdown HUVECS was 
assessed by DAF-2t levels.   
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Supplementary Figure 2.2.  PECAM-1 is not required for ionomycin-induced eNOS 
activation.  
 
PE-RC and PE-KO cells were stimulated with 1uM ionomycin and eNOS activation was 
assayed by Western blot. A Representative blot is shown (n=3, *P<0.01 vs PE-RC 0 min). 
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Supplemental Table 2.1. PCR and ChIP Primers 
Primers (Mus musculus) Sequence  
18s Fwd 5’-CATTCGAACGTCTGCCCTATC-3’ 
18s Rev 5’-CCTGCTGCCTTCCTTGGA-3’ 
NOSTRIN Exon 10 Fwd 5’-CCAGGCTCTAATGGAAGAAGAACTG-3’ 
NOSTRIN Exon 10 Rev 5’-AGACTTCCGTCGCTCTTTGTCC-3’ 
NOSTRIN Promoter Fwd 5’-GCAGAAGGAAAGGGTTTATTGTGGCCT-3’ 
NOSTRIN Promoter Rev 5’-GCAATAGGACCAGCTGCCCTCAA-3’ 
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Supplemental Table 2.2. Predicted STAT3 binding sites within the NOSTRIN promoter  
From JASPAR database 
308-317 TGACAGGA 
768-777 TTCCAGGCAT 
906-915 TTTCAGGAAA 
From Genomatix 
764-782 atcaaTTCCAGGCATccaga  
900-918 tcatTTCCTGAAAaagcac 
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CHAPTER III 
A mechanosensor mediates crosstalk between endothelial cells and cardiomyocytes 
to regulate cardiac function 
 
 
 
 
Overview 
Background – Idiopathic dilated cardiomyopathy (IDCM) represents one of the most 
common causes of heart failure and death in the United States. Recent work has identified a 
role for vascularization and hemodynamics in regulating cardiac function. In the present 
study, we investigate the role of the junctional adhesion molecule Platelet Endothelial Cell 
Adhesion Molecule (PECAM-1) in the regulation of cardiac function. 
Methods and Results –Conscious echocardiography revealed left ventricular (LV) chamber 
dilation and systolic dysfunction in PECAM-1-/- mice, which is further exacerbated in 
response to hemodynamic stress. Interestingly, despite deficits in cardiac function, 
cardiomyocytes isolated from PECAM-1-/- hearts displayed normal sarcomere structure and 
contractility. In the absence of PECAM-1, release of neuregulin (NRG-1) from endothelial 
cells (ECs) is deregulated, resulting in augmented phosphorylation of the NRG-1 receptor 
ErbB2. Furthermore, we observed aberrant activation of protein kinase A (PKA) and 
phospholamban, two proteins that are essential for the correct regulation of contractility in 
the cardiomyocyte, in the PECAM-1-/- mice.  
Conclusions – Here, we identify a novel role for PECAM-1 in regulating cardiac function 
both at baseline and in response to hemodynamic stress.  Based on our findings, we 
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propose that PECAM-1 is required for regulation of the NRG1 pathway in ECs, which 
ultimately acts on cardiomyocytes to affect cardiac contractility. These data highlight the 
importance of tightly regulated cellular communication for proper cardiac function. 
 
Introduction 
Endothelial cells (ECs) intimately associate with cardiomyocytes as each 
cardiomyocyte is surrounded by a dense network of capillary vessels comprised of ECs. The 
endothelium releases factors such as neuregulin (NRG-1), and nitric oxide (NO), that can 
affect numerous parameters of cardiomyocyte function, including their contractility	  1; 
cardiomyocytes, in turn, secrete factors that direct EC function	  2. Recent data provide a 
compelling link between EC dysfunction and the progression of dilated cardiomyopathy 
(DCM), a condition characterized by dilatation and impaired contraction of the heart that can 
lead to heart failure and sudden death	  3. Thus, to fully understand the biology and pathology 
of the heart, mechanisms of cellular crosstalk and their role in DCM must be investigated.  
Our current understanding of the pathways that regulate EC-cardiomyocyte crosstalk 
is lacking.  Importantly, we know that impaired release and/or activity of the molecules 
implicated in crosstalk can result in heart failure.  For example, the knockout mouse of 
apelin, a protein released by ECs and important for a number of physiological functions, 
develops impaired contractility with age	  4,	  5.  The NRG1-ErbB signaling pathway represents 
another pertinent example.  Interest in this pathway was generated following the observation 
that women treated with herceptin, a monoclonal antibody against the NRG-1 receptor 
ErbB2, have an increased risk for the development of heart failure	  6.  Numerous studies 
have supported a role for NRG1 and ErbB2 in heart failure; the ventricular-specific knockout 
of ErbB2 develops DCM with age	  7 and treatment with NRG-1 improves cardiac function in 
models of cardiomyopathy	  8. Finally, studies have suggested a role for hemodynamic stress, 
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hypoxia as well as mechanical load on cardiomyocytes and the extracellular matrix (ECM) in 
the development of DCM	  9.  
Mechanotransduction, or conversion of mechanical forces into biochemical or 
electrical signals, occurs in both cardiomyocytes and ECs	  10-­‐15.  Our own work has shown 
that the junctional cell adhesion molecule platelet endothelial cell adhesion molecule-1 
(PECAM-1) functions as a mechanosensory protein in ECs and confers the ability to sense 
and respond to the hemodynamic force of flowing blood	  10.  Although PECAM-1 initiates 
mechanosignaling specifically in ECs, its presence (or absence) can have profound 
consequences in the signals transmitted to other cell types, including vascular smooth 
muscle cells (VSMCs), and thus affect the physiology and pathology of the vessel as a 
whole. The PECAM-1-/- mouse is viable, but displays vascular defects in response to 
changes in hemodynamic forces. Specifically, PECAM-1-/- mice display impaired flow-
mediated dilation due to mis-regulated NO production	  16 and reduced VSMC relaxation	  17,	  18. 
In addition, our lab has shown that PECAM-1 deficiency results in impaired flow-mediated 
vascular remodeling that results in reduced VSMC activation and signaling	  19.  
 As EC-cardiomyocyte crosstalk is important in regulating cardiac function and 
cellular communication in the vessel wall is perturbed in the absence of PECAM-1, we 
hypothesized that cardiac function is impaired in PECAM-1-/- mice.  Here, we show that the 
absence of PECAM-1 results in impaired cardiac function associated with misregulated 
NRG-1β signaling in ECs and downstream defects in pathways that regulate cardiomyocyte 
contractility.  
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Materials and Methods 
Animals 
PECAM-1-/- C57BL/6 mice were kindly provided by Dr P. Newman (Blood Research Institute, 
Blood Center of Wisconsin, Milwaukee), bred in house and used in accordance with the 
guideline of the National Institute of Health and for the care and use of laboratory animals 
(approved by the Institutional Animal Care and Use Committees of the University of North 
Carolina at Chapel Hill). Male PECAM-1-/- and age-matched wild-type (WT) littermates. 
 
Cell Culture and Reagents 
PECAM-1-knockout (PE-KO) cells and cells reconstituted with murine full-length PECAM-1 
(PE-RC) were prepared as previously described	  16,	  20. 
 
Echocardiography Measurements 
Conscious echocardiography was performed as previously described using a Vevo 2100 
ultrasound biomicroscopy system	  21,	  22.  All LV dimension data are presented as the average 
of at least 3 independent waveforms.  
 
Transverse Aortic Constriction 
8-week old male WT and PECAM-/- mice were used for either sham operation or pressure-
overload induced by transverse aortic constriction as previously described	  22,	  23. Heart 
function was measured by echocardiography at 1 and 4 weeks after surgery.  
 
RNA isolation and Quantitative PCR 
Total RNA was isolated from mouse left ventricles using the Qiagen AllPrep Kit (Qiagen, 
Valencia, CA) following the manufacturer’s protocol. First-strand cDNA was transcribed 
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using random primers and SuperScript II Reverse Transcriptase (Invitrogen). Real-time 
quantitative PCR was performed using ABsolute SYBR Green ROX mix (Thermo Scientific). 
Primers used are found in Supplemental Table 3.3. 
 
Preparation of Lysates and Immunoblot Analysis 
Hearts were homogenized and protein was extracted in a RIPA lysis buffer (50mM HEPES, 
150mM NaCl, 2mM EDTA, 0.5% Triton X-100, 0.5% Na-Deoxycholate, 1% NP-40, 25mM β-
glycerophosphate, 10% glycerol, 1mM sodium orthovanadate, 1mM phenylsulphfonyl 
fluoride, 10µg/ml leupeptin, 10µg/ml aprotinin, 10mM sodium fluoride, 1mM sodium 
pyrophosphate, pH 7.2). Protein extracts (30µg) were subjected to Western blot analysis 
with antibodies against JNK, phospho-JNK, pTyr877ErbB2, pTyr1284ErbB4, PKA-C, and 
pThr197PKA, (Cell Signaling); pSer16PLN, PLN Clone 1 and GAPDH (Millipore). Vinculin 
was from Sigma. Immunocomplexes were detected using the Licor Odyssey secondary 
detection system. NRG-1β was a gift from D. Sawyer and used as previously described. 
Media was concentrated as previously described	  24 using Amicon Ultra-15 with Ultracel-3 
membrane (Millipore, Co, Bedford, MA).  
 
Histological analysis and immunohistochemistry 
Hearts were perfused with 4% paraformaldehyde for 24 hours and then switched to 70% 
ethanol. The hearts were then paraffin embedded and sectioned into 5µm sections and 
stained with hematoxylin and eosin to assess overall morphology	  22.  For cross-sectional 
analysis of cardiomyocytes and determination of capillary density, heart sections were 
stained with TRITC-conjugated lectin (Triticum vulgaris) and examined by fluorescence 
microscopy as previously described	  21,	  22.  
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Cardiomyocyte Isolation/Functional Assays  
Adult mouse cardiomyocyte isolation, experimentation and analysis from WT and PECAM-1-
/- mice were performed as previously described	  25,	  26.  
 
Transmission Electron Microscopy  
For electron microscopy, animals were euthanized and perfused with freshly made fixative 
containing 2% paraformaldehyde and 2.5% glutaraldehyde in 0.15M sodium phosphate 
buffer, pH 7.4. After perfusion, the hearts were removed and cut into 1-2 mm3 cubes and 
stored from several hours to overnight in the fixative before processing for electron 
microscopy. Sections were observed using a LEO EM910 transmission electron microscope 
operating at 80kV (Carl Zeiss SMT, Inc., Peabody, MA) and photographed using a Gatan 
Orius SC1000 Digital Camera and Digital Micrograph 3.11.0 (Gatan, Inc., Pleasanton, CA).  
 
Quantitation and Statistical Analysis 
The band intensity of immunoblots was quantitated using computer software (ImageJ).  
Each experimental group was analyzed using single factor analysis of variance (Excel; 
Microsoft).  Probability values were obtained by performing a 2-tailed Student t-test using 
the same program. Statistical significance was defined as P<0.05.  
 
Results 
PECAM-1-/- mice exhibit both systolic and diastolic dysfunction indicative of dilated 
cardiomyopathy 
To first assess the cardiac performance of PECAM-1-/- hearts, we performed transthoracic 
echocardiography in conscious 14-16 week old male mice (Figure 3.1). In the PECAM-1-/- 
mice, we observed a significant enlargement of the left ventricular (LV) chamber at end 
diastole (LVID;d) compared to WT mice (Figure 3.1A,B).  Echocardiography also revealed 
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impairment of LV function in PECAM-1-/- hearts, as evidenced by decreased ejection fraction 
(EF) and fractional shortening (FS) (Figure 3.1C).  Interestingly, there was no significant 
difference in wall thickness at end diastole (Supplemental Table 3.1).  We did, however, 
observe an increase in left ventricular mass (Figure 3.1D). This phenotype was present at 
every post-natal time point evaluated (Figure 3.1E, F and Supplemental Table 3.2). In 
summary, the echocardiographic data suggest that PECAM-1-/- mice have LV chamber 
dilation and systolic dysfunction, suggestive of dilated cardiomyopathy (DCM).  
 Studies have shown that increased blood pressure (hypertension) can lead to heart 
failure	  27,	  28. To exclude the possibility that differences in blood pressure account for the 
impaired cardiac function in the PECAM-1-/- mouse, we measured mean arterial pressures 
(MAP) in conscious 12-14 week old mice. There was no significance difference in pressures 
between genotypes (Supplemental Figure 3.1), suggesting that cardiac dysfunction in the 
PECAM-1-/- animals is not associated with hypertension.  
 
Phenotypic characterization of PECAM-1-/- mice  
 Reactivation of the fetal gene program is a common marker for various cardiac 
pathologies, including hypertrophy and DCM	  29.  We therefore assessed fetal gene 
expression in adult WT and PECAM-1-/- hearts by quantitative PCR.  The expression of β-
myosin heavy chain (βMHC), atrial natriuretic peptide (ANP) and α-skeletal actin (αSka) 
were significantly increased in PECAM-1-/- hearts compared with WT littermates (Figure 
3.2A).  Interestingly, the increase in βMHC levels was not accompanied by a corresponding 
decrease in αMHC expression; this switch in isoform expression is frequently observed in 
mouse models of DCM	  30.  
We next investigated baseline cardiomyocyte area and capillary density in WT and 
PECAM-1-/- hearts. Cardiomyocyte cross-sectional area measurements revealed that 
	   55	  
cardiomyocytes in PECAM-1-/- hearts were slightly larger than WT cardiomyocytes (174.8 
µm2 vs. 162.8 µm2), although this did not reach statistical significance (Figure 3.2B). Recent 
studies have suggested a role for defective vascularization in the pathogenesis of idiopathic 
DCM (IDCM)	  3.  Because PECAM-1 is expressed in ECs, and ECs line blood vessel walls, 
we hypothesized that differences in cardiac vascularity might account for differences in 
cardiac function of PECAM-1-/- animals.  There were no obvious defects in coronary artery 
structure or number detected in the PECAM-1-/- hearts (data not shown). We also measured 
capillary density by TRITC-lectin staining and did not observe any differences between 
genotypes (Figure 3.2B).  Despite having normal vascular architecture, the possibility exists 
that there is impaired tissue perfusion, which could compromise cardiac function. To 
address this possibility, we performed staining for tissue hypoxia and did not find any 
indication of hypoxia in PECAM-1-/- heart tissue (Supplemental Figure 3.2).  
 The fundamental contractile unit of cardiac muscle is the sarcomere.  Previous 
studies have shown that defects in sarcomere protein expression and structure can lead to 
DCM	  31. In order to determine if alterations in sarcomere structure could explain the impaired 
contractility of the PECAM-1-/- hearts, we performed transmission electron microscopy 
(TEM).  We did not detect any differences sarcomere organization or size between the WT 
and PECAM-1-/- mice (Figure 3.2C). When taken together with the vascular data, our studies 
suggest that the impaired cardiac function in the PECAM-1 null animals is not due to 
structural or architectural defects in the heart.  This leads us to hypothesize that impaired 
EC-cardiomyocyte communication may be responsible for the observed phenotype.  
 
Increased systolic dysfunction in PECAM-1-/- mice after biomechanical stress 
To further explore the role of PECAM-1 in regulating cardiac function, we subjected 
PECAM-1-/- mice to transverse aortic constriction (TAC), a well-established model of 
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pressure overload.  Following partial ligation of the aorta, there is an increase in 
biomechanical and hemodynamic stress on the heart as well as increased demand on the 
cardiomyocytes. This increased stress induces the formation of concentric hypertrophy as a 
mechanism of compensation	  23. In addition to effects on cardiomyocytes, the hemodynamic 
environment in the coronary vessels is also perturbed	  32. Previous studies have shown that 
PECAM-1-/- mice have impaired blood flow-mediated responses including impaired vascular 
remodeling and flow-mediated dilation	  17,	  19,	  33.  Based on these studies, we hypothesized 
that PECAM-1-/- mice would have impaired remodeling after TAC.   As expected, WT mice 
subjected to TAC displayed increased thickness of both the intraventricular septum and 
posterior wall (Figure 3.3A, B; Supplemental Table 1), accompanied by preservation of FS 
and EF (Figure 3.3C, D). In contrast, 4 weeks after TAC, PECAM-1-/- mice did not exhibit 
any significant increase in LV wall thickness.  Additionally, these animals had a further 
increase in LV chamber size (Supplemental Table 3.1) and a significant deterioration in 
cardiac function (Figure 3.3C). 
To assess morphological changes to the heart tissue after TAC, we analyzed the 
cross-sectional area of cardiomyocytes from WT and PECAM-1-/- hearts (Figure 3.4A).  After 
4 weeks of TAC, WT mice showed a significant increase in cardiomyocyte area, whereas 
the hypertrophic response was impaired in the PECAM-1-/- hearts (316.0 µm2 vs. 247.5 µm2) 
(Figure 3.4B). Similarly, we observed an increase in capillary density in WT mice after TAC, 
but this response was blunted in PECAM-1-/- mice (Figure 3.4B). There was no difference in 
fibrosis observed between genotypes (Supplemental Figure 3.4). 
Another common feature of pathological hypertrophy is upregulation of fetal gene 
expression	  29,	  34. We measured changes in gene expression after 4 weeks of TAC in the 
hearts (Figure 3.4C).  Expression of βMHC, ANP, and αSka were increased in both WT and 
PECAM-1-/- hearts 7 days after TAC, although this increase was significantly reduced in 
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PECAM-1-/- animals (14-fold in WT vs. 4-fold in PECAM-1-/- for βMHC).  This impaired 
activation is in agreement with the reduced hypertrophic response seen in the PECAM-1-/- 
mice (Figure 3.3). To gain insights into signaling pathways that might be affected in the 
absence of PECAM-1, we examined the MAPK pathway, which is implicated in mediating 
the development of cardiac hypertrophy	  35,	  36. Immunoblots of heart lysates revealed blunted 
JNK phosphorylation in the PECAM-1-/- hearts after TAC compared to WT hearts (Figure 
3.4D).  There was no difference in activation of other hypertrophic regulators between 
genotypes.  
 
Cardiomyocytes isolated from PECAM-1-/- hearts display normal contractility  
Endothelial cell-cardiomyocyte crosstalk is thought to play an important role in 
regulating cardiac function	  2. As PECAM-1 is not expressed in cardiomyocytes 
(Supplemental Figure 3.3)	  37,	  38, we reasoned that the absence of PECAM-1 in ECs might 
lead to impaired EC-cardiomyocyte communication.  Accordingly, we hypothesized that 
cardiomyocytes isolated from PECAM-1-/- hearts should behave like cardiomyocytes isolated 
from WT hearts.  Basal rates of contraction and relaxation of cardiomyocytes isolated from 
PECAM-1-/- hearts were indistinguishable from those isolated from WT hearts. Additionally, 
we observed no differences in the maximum and minimum cardiomyocyte length (Table 
3.1).  These findings seem to be at odds with those made by echocardiography, which 
revealed impaired systolic and diastolic function in PECAM-1-/- hearts. They suggest that 
cardiomyocytes, when isolated and in the absence of EC input, are capable of contracting 
normally, whether they are isolated from PECAM-1-/- or WT hearts. Interestingly, the 
PECAM-1-/- cardiomyocytes have an enhanced response to isoproterenol treatment. The 
significance of this observation is currently being investigated. 
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Impaired Neuregulin-ErbB signaling in the PECAM-1-/- mice 
A complex signaling network exists between cell types within the heart. Crosstalk 
between ECs and cardiomyocytes is mediated, in part, by secreted factors such as VEGF, 
NO, and NRG1	  2.  Interestingly, NRG1 and ErbB knockout mice display defects in cardiac 
function, including DCM	  39,	  40.  NRG-1 is a member of the EGF family of proteins and is able 
to bind and activate ErbB receptors within the heart.  Upon activation, ErbB receptors signal 
through phosphoinositide-3 kinase and Akt to modulate cardiomyocyte contractility	  41,	  42. It 
has previously been shown that release of the NRG1β isoform from ECs is mediated by 
reactive oxygen species (ROS)	  43. Furthermore, coronary arteries from PECAM-1 null mice 
have increased ROS production	  17. We therefore investigated if the impaired contractility in 
PECAM-1-/- mice is associated with defects in the NRG1 pathway.  We first assayed ROS 
production in vitro using PECAM-1 knockout (PE-KO) and PECAM-1 expressing (PE-RC) 
ECs. There was a significant increase in ROS production from the PE-KO cells correlating 
with observations in vivo (Figure 3.5A). To determine levels of NRG1 release from ECs, we 
measured NRG-1β release by immunoblot analysis of conditioned cell media from PECAM-1 
knockout (PE-KO) and PECAM-1 expressing (PE-RC) ECs. Interestingly, we observed 
increased NRG-1β in the media of PE-KO cells compared to PE-RC cells (Figure 3.5B).  To 
determine if these observations translated in vivo, heart lysates from WT and PECAM-1-/- 
animals were assessed for NRG-1β release. Similar to our observations in vitro, we found 
higher levels of NRG-1β in PECAM-1-/- hearts (Figure 3.5C).   
We next wanted to determine if the increased NRG-1β levels correlated with 
increased activity of its receptor.  Importantly, we observed increased phosphorylation of 
ErbB2 in PECAM-1-/- hearts (Figure 3.5D).  These data suggest that misregulated NRG-1β 
release in the PECAM-1-/- hearts could impair cardiac contractility via overactivation of ErbB 
receptor signaling in cardiomyocytes. Importantly, we did not observe any difference 
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between genotypes in expression of either total NRG1 or ErbB2 levels by both Western blot 
and quantitative PCR (data not shown).  
NRG1/ErbB signaling affects the activity of proteins that mediate calcium handling 
from the sarcoplasmic reticulum of cardiomyocytes and proper regulation of these proteins 
is required for normal cardiac contractility.  Protein kinase A (PKA) and phospholamban 
(PLN), a regulator of the Ca2+-ATPase (SERCA2), are two important proteins in this 
process. Previous studies have shown that treatment of cardiomyocytes with NRG1 induces 
an increase in PLN phosphorylation	  44.  Additionally PKA is known to mediate PLN 
phosphorylation on serine residue 16	  45. We performed Westerns blots on heart tissue to 
assess PLN phosphorylation status and found a significant increase in pSer16PLN in 
PECAM-1-/- compared to WT hearts (Figure 3.5E,F).  Similar to PLN, we found significant 
increases in pThr147PKA in the PECAM-1-/- hearts (Figure 3.5E and 3.5G). Importantly, 
levels of phosphorylation of threonine residue 17, a Ca2+-calmodulin-dependent protein 
kinase II (CAMKII)-dependent phosphorylation site, were unaffected in the PECAM-1-/- (data 
not shown). Overall, these data suggest that impaired NRG-1 signaling in PECAM-1-/- hearts 
may impair cardiac contractility through mis-regulation of PKA and PLN. 
 
Discussion 
The findings presented here support a model in which PECAM-1, expressed in ECs 
and not cardiomyocytes, is able to modulate cardiomyocyte signaling and function, both 
under baseline conditions and in response to hemodynamic stress (Figure 3.5H). In the 
absence of PECAM-1, we observed increased NRG-1β release and concomitant increased 
phosphorylation of ErbB receptors. It is well established that signaling downstream of the 
ErbB receptors influences calcium handling and cardiomyocyte function	  44.  Therefore, we 
propose that the absence of PECAM-1 facilitates increased NRG1β release from ECs, which 
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binds to the ErbB family of receptors on cardiomyocytes, leading to misregulated calcium 
handling and, ultimately, defects in cardiac contractility.  It should be noted that mutations to 
PLN can lead to DCM in both human and mouse models	  46,	  47. Additionally, constitutive 
activation of PKA can lead to impaired contractility and DCM	  48. 
The role of cardiomyocytes in regulating adult cardiac function has been well 
documented. This regulation is clinically relevant as mutations in sarcomere protein genes 
account for 10 percent of familial DCM	  49.  Additionally, mouse models with mutations in 
sarcomere protein often develop severe forms of DCM (reviewed in	  50). Because the 
PECAM-1-/- animals have normal sarcomere structure, it is not surprising that they exhibit a 
mild form of DCM.  In addition to normal sarcomere structure, the vasculature appears 
unperturbed, which is another potential risk factor for DCM development	  51-­‐53.  The fact that 
there are no obvious structural disruptions to either network implies that misregulated 
cellular communication results in impaired cardiac function. It is also possible that the 
PECAM-1-/- phenotype is mild due to compensation for the increased NRG-1/ErbB signaling.  
One result that points to this possibility is the isoproterenol data.  Although both genotypes 
had a positive inotropic response of cardiomyocytes to isoproterenol (Table 3.1) this 
response was significantly enhanced in cardiomyocytes isolated from PECAM-1-/- hearts, 
suggestive of upregulation of the β-adrenergic pathway. This would not be surprising, as 
increased NRG1 is associated with decreased contractility through the muscarinic pathway	  
54, and proper coordination of these two pathways is required for contractility and efficient 
heart function.  
  Although we cannot exclude the possibility that other PECAM-1-expressing cell types 
may contribute to the impaired systolic function in the PECAM-1-/- mice, several pieces of 
data argue against this idea.  First, previous studies have shown that there are no 
differences in either leukocyte or platelet counts in PECAM-1-/- mice	  55. Second, on a 
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C57Bl/6 background, no differences in platelet activation	  56 or leukocyte emigration have 
been observed in PECAM-1-/- animals	  55.  In addition, each cardiomyocyte is intimately 
associated with the surrounding EC-derived vasculature facilitating a unique interface for 
cellular crosstalk.  
To date, the rather intuitive, consensus in the field is that EC signaling can affect 
global heart function. However, studies supporting this thinking are limited. There are only a 
handful of reports of EC-specific knockout animals demonstrating impaired cardiac 
contractility. A role for vascular density in regulating heart growth and function has recently 
been reported	  57.  Importantly, not all EC knockout models display a basal cardiac 
phenotype.  For example, the HIF2α EC-specific knockout has normal contractility, but once 
challenged by TAC, there is rapid decompensation to heart failure	  58. Previously, work in the 
caveolin-1-/- global KO mouse showed development of DCM at 5 months of age	  59.  This was 
attributed to misregulation of eNOS/NO signaling in non-myocytes, a signaling pathway 
thought to play an important role in EC-cardiomyocyte crosstalk. However, additional studies 
suggest that Cav1 is required in fibroblasts	  60. In general, although it is accepted that ECs 
release molecules that can affect cardiomyocyte function, the mechanisms that regulate this 
release remain unclear.  
 Another important observation from our studies is the impaired remodeling in the 
PECAM-1-/- mice after TAC.  This phenotype is likely due to a mechanism independent of 
the impaired NRG-1β signaling.  We know from our previous studies that PECAM-1-/- 
animals have impaired remodeling in response to changes in hemodynamic stress in 
models of carotid artery ligation and impaired collateral remodeling. In these models, the 
absence of PECAM-1 prevents the detection of changes in blood flow and subsequent 
activation of signaling pathways. It is likely that a similar phenomenon is occurring in the 
heart, as TAC dramatically changes the hemodynamic environment.  
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 Currently, our understanding of the role of shear stress and hemodynamic forces in 
regulating heart function is limited.  Studies in zebrafish have shown that manipulating the 
flow environment, either genetically or mechanically, has profound effects on heart formation	  
61.  Additionally, loss of the primary cilium in mouse causes significant changes to heart 
formation	  62. Our data suggest that the PECAM-1-/- mouse is a relevant model to study the 
role of shear stress on adult heart function. When the hemodynamic environment in 
manipulated (via TAC), PECAM-1-/- animals show impaired remodeling compared to WT 
animals.  Using this model may help elucidate signaling pathways that are required in shear 
stress signaling in both cardiac endothelial cells and the heart. Additionally, this study 
furthers our understanding of the potential causes of DCM.  
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Figures  
 
Figure 3.1. PECAM-1-/- mice have increased chamber size with systolic and diastolic 
dysfunction. 
 
 
A. Representative image of M-Mode echocardiography for baseline heart function in age-
matched adult WT and PECAM-1-/- mice. B-C. Echocardiographic measurement assessment 
of left ventricular dilation and cardiac function (ejection fraction, %EF, fractional shortening, 
%FS).  Echocardiography results represent at least 10 mice per group (*P<0.01).  
Measurements were collected at the level of the papillary muscle in M-mode. D. Analysis of 
left ventricle weight to tibia length to normalize left ventricular mass (n=10/genotype, 
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*P<0.005). E-F. Echocardiographic measurement assessment of left ventricular function by 
fractional shortening (E) and ejection fraction (F). Echocardiography results represent at 
least 10 mice per group (*P<0.01).  
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Figure 3.2. Normal cellular architecture in PECAM-1-/- hearts. 
 
 
A. Quantitative real-time RT-PCR of cardiac fetal gene expression in 12-week-old male 
mice.  All mRNA species were quantified relative to 18s housekeeping gene expression and 
presented as fold change (arbitrary units [AU]) relative to WT mice. (n=3/genotype, *P<0.01 
#P<0.05). βMHC indicates β-myosin heavy chain; ANP, atrial natriuretic peptide; αSka, α 
skeletal actin; αMHC, α myosin heavy chain. B. TRITC-lectin stained sections for baseline 
cardiomyocyte cross-sectional area and capillary density in WT and PECAM-1-/- mice. Scale 
bar 20µm (n=3-4/genotype, **P<0.01). C. The ultrastructure of cardiac muscle from WT and 
PECAM-1-/- mice by transmission electron micrograph. 10000X and 25000X representative 
images shown, scale bars 2µm and 1µm, respectively. 
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Figure 3.3. PECAM-1-/- mice have impaired response to TAC.  
 
A. 8-week-old WT and PECAM-1-/- mice underwent either sham or TAC surgeries. 
Representative H&E stained sections are shown. B. Left ventricular anterior wall dimensions 
in diastole for sham, 7 day and 28 day WT and PECAM-1-/- hearts (n= 6/genotype for sham, 
n=10/genotype for TAC, *P<0.001 #P<0.005) C. Fractional shortening and ejection fraction 
for sham, 7 day and 28 day hearts (n= 6/genotype for sham, n=10/genotype for TAC, 
*P<0.005 **P<0.02, #P<0.05). 
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Figure 3.4. Impaired cellular activation and remodeling after TAC in PECAM-1-/- mice. 
 
A. TRITC-lectin staining of sham and 4 week TAC WT and PECAM-1-/- hearts. B. 
Quantitation of staining in A for baseline and 28 days post-TAC cardiomyocyte cross-
sectional area and capillary density in WT and PECAM-1-/- mice (n=3-4/genotype, *P<0.001, 
#P<0.05). C. Quantitative real-time RT-PCR of cardiac fetal gene expression in 12-week-old 
male mice.  All mRNA species were quantified relative to 18s housekeeping gene 
expression and presented as fold change (arbitrary units [AU]) relative to sham mice. 
(n=3/genotype, *P<0.01). D. Representative Western blot for pThr183/pTyr185JNK in sham 
and 7d post-TAC WT and PECAM-1-/- hearts.   
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Table 3.1. Contractile parameters in adult myocytes isolated from WT and PECAM-1-/- 
mice 
 Wild-Type (n = 6) PECAM-1-/- (n = 7) 
 Basal Iso (10-7 M) Basal Iso (10-7 M) 
-dL/dt (µM/ms) -0.283±0.02 -0.365±0.01 -0.299±0.02 -0.419±0.01a 
+dL/dt (µM/ms) 0.259±0.02 0.303±0.01 0.280±0.01 0.357±0.01b 
Maximum Length (µM) 126.4±2.8 126.9±3.7 128.2±3.6 134.4±3.6 
Minimum Length (µM) 105.4±2.7 97.9±2.6 105.6±2.6 103.22±3.4 
 
a p<0.015 PECAM-1-/- vs WT 
b p<0.005 PECAM-1-/- vs WT 
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Figure 3.5. Misregulated NRG-1/ErbB signaling in PECAM-1-/- hearts. 
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A. Confluent monolayers of PE-RC and PE-KO cells were serum-starved for 24 hours then 
loaded with 2,7-H2DCFDA (10µmol/L for 30 minutes at 37°C) then lysed. Fluorescence was 
measured using a plate reader. Fluorescence was normalized to total protein levels in the 
lysate (n=7, *P<0.01). B. Quantitation of Western blot for NRG-1β release from PE-RC and 
PE-KO cells. Media was collected after 24hrs and concentrated. Concentrated media was 
then run on a polyacrylamide gel (n=5, *P<0.05). C. Quantitation of Western blot for NRG-1β 
in heart tissue from WT and PECAM-1-/- hearts. (n=3/genotype, *P<0.05). D. Representative 
Western blots for phospho-ErbB2 (n=6/genotype). E. Levels of pSer16PLN and 
pThr147PKA were assayed by Western blot. Samples were normalized to total PLN and 
total PKA respectively. Quantitation is shown for pSer16PLN in (F) and pThr147PKA in (G) 
(n=6/genotype, *P<0.03 #P<0.005). H. Model of PECAM-1 regulation of cardiac contractility.  
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Supplemental Materials and Methods 
Blood pressure measurements 
Blood pressure was non-invasively measured by determining the tail blood volume with a 
volume pressure-recording sensor and an occlusion tail-cuff (CODA System, Kent Scientific, 
Torrington, CT).  
 
Tissue hypoxia staining 
Tissue hypoxia was assessed using the HypoxyprobeTM-1 Kit (Hypoxyprobe, Inc. Burlington, 
MA) according to the manufacturer’s instructions and as previously described	  63. Briefly, 
animals were injected i.p. with 60mg/kg hypoxyprobe for 60 minutes. Hearts were then 
harvested and fixed in 4% PFA, embedded in paraffin and sectioned at 8 µm. Tissue 
sections were stained with the Hypoxyprobe-1 antibody and visualized using DAB. 
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Supplemental Figure Legends 
 
Supplemental Table 3.1. Echocardiographic data from WT and PECAM-1-/- mice pre- 
and post-TAC 
 Wild Type (n=5-12) PECAM-1-/- (n=5-12) 
 Pre-TAC 28d TAC Pre-TAC 28d TAC 
Heart Rate (BPM) 710 ± 15.45 680 ± 8.8 660 ± 12.5b 660 ± 10.6 
IVS;d (mm) 1.01 ± 0.02 1.23 ± 0.3e 1.06 ± 0.02 0.99 ± 0.05d 
IVS;s (mm) 1.70 ± 0.02 1.86 ± 0.04 1.58 ± 0.02 1.41 ± 0.16 
LVPW;d (mm) 0.96 ± 0.01 1.20 ± 0.05e 0.99 ± 0.02 0.99 ± 0.05 
LVPW;s (mm) 1.52 ± 0.02 1.65 ± 0.04 1.4 ± 0.03 1.25 ± 0.06 
LVID;d (mm) 2.94 ± 0.17 2.79 ± 0.1 3.29 ± 0.12b 3.43 ± 0.31 
LVID;s (mm) 1.38 ± 0.10 1.56 ± 0.11 2.06 ± 0.08 2.54 ± 0.4 
LV Vol;d (µl) 34.9 ± 5.1 29.6 ± 2.7 44.6 ± 3.9 49.6 ± 11.2 
LV Vol;s (µl) 5.33 ± 1.0 7.04 ± 1.3 14.2 ± 1.4 28.48 ± 12 
EF% 85.5 ± 0.87 76.8 ± 2.5 68.2 ± 1.14a 52.0 ± 9.8c 
FS% 48.3 ± 2.4 44.2 ± 2.2 37.2 ± 0.88a 26.8 ± 6.2c 
 
HR, heart rate; IVS, interventricular septum; LVPW, left ventricular posterior wall; LVID, left ventricular internal 
dimension; LV vol, left ventricular volume; EF, ejection fraction; FS, fractional shortening. 
 
aP<0.005 PECAM-1-/- vs WT pre-TAC 
bP<0.01 PECAM-1-/- vs WT pre-TAC 
cP<0.05 PECAM-1-/- vs WT 28d TAC 
dP<0.05 PECAM-1-/- vs WT 28d TAC 
eP<0.05 WT pre- vs 28d TAC 
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Supplemental Table 3.2. Echocardiographic data from aging WT and PECAM-1-/- mice  
 Wild Type (n=10) PECAM-1-/- (n=10) 
 4 weeks 8 weeks 12 weeks 4 weeks 8 weeks 12 weeks 
Heart Rate 
(BPM) 684 ± 24.4 737 ± 8.23 725 ± 9.3 612 ± 24.3 664 ± 22.1 678 ± 17.1 
IVS;d (mm) 0.73.3 ± 0.01 0.88 ± 0.03 0.98 ± 0.03 0.70 ± 0.03 0.86 ± 0.02 0.99 ± 0.02 
IVS;s (mm) 1.21 ± 0.03 1.46 ± 0.03 1.62 ± 0.02 1.07 ± 0.05c 1.35 ± 0.04c 1.57 ± 0.04 
LVPW;d 
(mm) 0.72 ± 0.02 0.84 ± 0.03 0.91 ± 0.03 0.62 ± 0.03
a 0.82 ± 0.04 0.92 ± 0.04 
LVPW;s 
(mm) 1.15 ± 0.04 1.33 ± 0.04 1.49 ± 0.05 0.93 ± 0.02
a 1.2 ± 0.06 1.34 ± 0.05 
LVID;d (mm) 2.42 ± 0.1 2.69 ± 0.07 2.89 ± 0.05 2.77 ± 0.1c 3.33 ± 0.2a 3.19 ± 0.13c 
LVID;s (mm) 1.36 ± 0.08 1.5 ± 0.05 1.53 ± 0.06 1.89 ± 0.09a 2.19 ± 0.2a 2.08 ± 0.1a 
LV Vol;d (µl) 21.3 ± 1.87 27.1 ± 1.68 31.2 ± 1.25 29.5 ± 2.8c 46.8 ± 6.0a 42.5 ± 4.1c 
LV Vol;s (µl) 4.9 ± 0.6 6.17 ± 0.5 6.52 ± 0.63 11.4 ± 1.4a 14.9 ± 3.2a 14.7 ± 2.5b 
EF% 76.9 ± 2.2 77.3 ± 1.0 79.8 ± 1.5 61.6 ± 2.1a 64.9 ± 2.5a 65.2 ± 2.4a 
FS% 44.1 ± 2.0 44.3 ± 0.9 47.2 ± 1.5 31.9 ± 1.5a 34.7 ± 1.7a 34.0 ± 1.8a 
 
HR, heart rate; IVS, interventricular septum; LVPW, left ventricular posterior wall; LVID, left ventricular internal 
dimension; LV vol, left ventricular volume; EF, ejection fraction; FS, fractional shortening. 
 
aP<0.005, bP<0.01, cP<0.05 All statistics were calculated PECAM-1-/- vs WT at corresponding age 
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Supplemental Figure 3.1. Mean arterial pressure (MAP) from PECAM-1-/- mice similar 
to WT mice.  
 
 
Blood pressures from WT and PECAM-1-/- mice were performed by tail-cuff measurement 
(n=9-10/genotype). 
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Supplemental Figure 3.2. No evidence for hypoxia in PECAM-1-/- hearts 
 
WT and PECAM-1-/- were injected with Hypoxyprobe-1TM 60 minutes prior to sacrifice.  The 
tissue was fixed, paraffin-embedded and sectioned.  There was no apparent positive 
staining in either genotype.  
	   76	  
 
Supplemental Figure 3.3. No difference in fibrosis between genotypes after TAC.  
 
Masson’s trichrome staining in either sham or 28 days after TAC in WT and PECAM-1-/- 
mice to look at fibrosis. 
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Supplemental Figure 3.4. Adult mouse cardiomyocytes do not express PECAM-1. 
 
 
qPCR was performed on RNA isolated from two lines of mouse endothelial cells as well as 
mouse cardiomyocytes (HL1) cells. No expression was detected in the CMs compared to 
the robust signal from the endothelial cells. 
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Supplemental Table 3.3. Primers used for quantitative PCR 
Primers Sequence 
ANP For 5’ TGGGACCCCTCCGATAGATC 3’ 
 Rev 5’ TCGTGATAGATGAAGGCAGGAA 3’ 
βMHC For 5’ TTGAGAATCCAAGGCTCAGC 3’ 
 Rev 5’ CTTCTCAGACTTCCGCAGGA 3’ 
αMHC For 5’ CTACGCGGCCTGGATGAT 3’ 
 Rev 5’ GCCACTTGTAGGGGTTGAC 3’ 
αSK-Actin For 5’ CAGCTCTGGCTCCCAGCACC 3’ 
 Rev 5’ AATGGCTGGCTTTAATGCTTCA 3’ 
18s For 5’ CATTCGAACGTCTGCCCTATC 3’ 
 Rev 5’ CCTGCTGCCTTCCTTGGA 3’ 
PECAM-1 For 5’ CACCTCGAAAAGCAGGTCTC 3’ 
 Rev 5’ CGTTATACACCATCGCATCG 3’ 
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CHAPTER IV. 
 
Conclusions and Perspectives 
 
 
 
 
Overview  
In chapters II and III of this dissertation, I have identified two new aspects of 
PECAM-1 biology: 1. Regulation of eNOS activity via a novel mechanistic pathway and 2. A 
role for PECAM-1 in regulation of heart function via modulation of EC-CM crosstalk.  
PECAM-1 was originally identified in 1990 as a glycoprotein expressed on the surface of 
endothelial cells (ECs)	  	  1. Over the past 22 years, we have learned a tremendous amount 
about its complex biology, which ranges from junctional adhesion molecule to a more 
recently identified role as an endothelial mechanosensor.  My work, described in Chapter II, 
identifies a novel pathway by which PECAM-1 modulates eNOS localization and activity in 
ECs.  In Chapter III, I describe the mechanism through which PECAM-1 expression leads to 
normal cardiac function. This is a novel role for PECAM-1, as relatively little attention has 
been paid to its role in organ systems, due in part to the viability and phenotypic normality of 
the PECAM-1-/- mouse. 
 While both Chapter II and III provide novel insights into PECAM-1 biology, they also 
highlight important underlying concepts in the field of vascular biology.  In this chapter I will 
address relevant topics and unanswered questions generated by my research, such as the 
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role of shear stress both in vitro and in vivo.  I conclude with a discussion of how my work 
furthers our understanding of cell signaling in the cardiovascular system. 
 
CHAPTER II: PECAM-1 REGULATES eNOS ACTIVTY AND LOCALIZATION THROUGH 
STAT3-DEPENDENT NOSTRIN EXPRESSION 
 
 In Chapter II, I set out to identify the mechanisms by which PECAM-1 regulates 
basal eNOS activity.  Ultimately my research identified a novel-signaling pathway in ECs 
that regulates eNOS function.  However, despite thorough characterization of this pathway, 
several important questions remain, including definition of a role for shear stress and the 
mechanism by which JAK/STAT signaling regulates NOSTRIN expression and subsequent 
eNOS activity. 
 
The role of shear stress 
One of the most significant inputs to the endothelium is the frictional shear stress of 
blood flow.  Shear stress plays an integral role in regulating both normal physiology, as well 
as vascular pathologies including the development of atherosclerosis	  2.  As early as the 
1960s, researchers and physicians recognized the non-uniform distribution of 
atherosclerotic lesions; they preferentially formed in large arteries at branch points or areas 
of high curvature, such as the inner curve of the aortic arch	  3. It was hypothesized that 
hemodynamic force, or shear stress, was responsible for this focal distribution.  In these 
regions of the vasculature, blood flow, and consequently shear stress, is low and disturbed.  
A considerable amount of research has been done in the last 50 years to identify how the 
vessel, and more specifically ECs, can detect differences in shear stress. We now know that 
ECs are equipped with mechanosensory molecules that detect mechanical forces such, as 
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shear stress, and trigger diverse EC signaling cascades in response to distinct mechanical 
inputs. 
Of particular interest to our lab is a recently described mechanosensory complex 
consisting of PECAM-1, VE-Cadherin, and VEGFR2	  4.  In this complex, PECAM-1 functions 
as the force transducer, converting shear stress into an intracellular response.  In the 
absence of PECAM-1, ECs are unable to activate shear stress-responsive signaling 
pathways such as Akt and Erk1/2	  	  4.  Thus, both the PECAM-1-/- animals, as well as ECs 
isolated from these mice, are useful tools for identifying the role of shear stress in 
physiologically relevant pathways	  5,	  6.  For my dissertation research, I have utilized these 
tools to answer questions about PECAM-1 cardiovascular biology. 
PECAM-1 is required for eNOS activation in response to shear stress; there is no 
increase eNOS phosphorylation in ECs lacking PECAM-1 (PE-KO).  However, my research 
revealed that despite the requirement for PECAM-1 in response to shear, PE-KO cells have 
higher basal levels of eNOS phosphorylation, which correlates with increased NO 
production.  This was an intriguing observation and led us to characterize a novel 
mechanism by which PECAM-1 regulates eNOS activity and localization through the eNOS 
trafficking protein NOSTRIN described in Chapter II.  These observations, coupled with what 
we know about PECAM-1 biology, lead us to ask whether shear stress plays a role in 
mediating NOSTRIN expression. 
NOSTRIN was first described a decade ago, and the majority of work done in the 
years since has focused on its role in directing eNOS localization and activity	  7.  More recent 
work has identified a role for NOSTRIN in FGF-mediated signaling and vascular 
development independent of its association with eNOS	  8.  Given that most studies have 
focused on the function of the protein, relatively little is known about how NOSTRIN 
expression is regulated.  My work has shown that NOSTRIN expression is regulated, in part, 
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by the transcription factor STAT3, and through direct interaction of STAT3 with the 
NOSTRIN promoter. To address whether shear stress mediates NOSTRIN expression, I 
have done preliminary experiments in PECAM-1 expressing cells.  After 4 hours of laminar 
shear stress, I observed an increase in NOSTRIN expression (as measured by qPCR).  This 
suggests that NOSTRIN expression is shear stress-responsive.  However, it remains 
unclear if this increase in expression occurs in a PECAM-1/STAT3-dependent manner.  
In vivo, the distribution of eNOS is modified by different patterns of shear stress 
(laminar vs. disturbed)	  9.  This is particularly relevant in regions prone to atherosclerosis 
where redistribution of eNOS correlates with decreased NO production	  10. Therefore, it may 
be possible that distinct shear stress patterns direct changes in NOSTRIN expression.  This 
could account for changes in eNOS distribution.  One might hypothesize that in 
atheroprotective regions, NOSTRIN expression levels would also be high.  Conversely, in 
atheroprone areas where shear stress is disturbed, NOSTRIN expression would be low.  
Thus eNOS would be mislocalized and subsequently NO production would be reduced. 
Understanding the complex relationships between these signaling pathways might help 
further our understanding about the production of NO, a critical mediator of vascular health 
and disease.  
 
PECAM-1 regulation of JAK/STAT activity  
In Chapter II, we describe a role for JAK/STAT3 signaling in the regulation of 
NOSTRIN expression.  PECAM-1 is required for this signaling, as in its absence, we 
observe reduced STAT3 phosphorylation and reduced NOSTRIN expression. Previous 
studies have shown that PECAM-1 can act as a scaffold for both STAT3 and STAT5, 
facilitating their activation	  11, but it is unclear how PECAM-1 promotes STAT 
phosphorylation.  STAT3 is activated by phosphorylation of either tyrosine residue 705 
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(Tyr705) or serine residue 727 (Ser727), both of which are important for influencing its 
transcriptional activity.  It is thought that protein kinase C delta (PKCδ) phosphorylates 
Ser727, whereas the more canonical janus kinase (JAK) phosphorylates Tyr705	  12.  In 
agreement with previous studies, the PECAM-1 KO ECs have reduced Tyr705 
phosphorylation. By treating the PECAM-1 expressing (PE-RC) ECs with the JAK/STAT3 
inhibitor, cucurbitacin, we are able to phenocopy the PE-KO cells and reduce NOSTRIN 
expression.  This suggests that although Ser727 is an important activation site, PKCδ is less 
likely to be important in our system.  Other studies have implicated a role for Src in 
regulating STAT3 activation	  13,	  14.   Because PECAM-1 facilitates Src activation in response 
to specific stimuli, it is also possible that Src is important in controlling STAT3 activity.  
We have yet to investigate the activity of PKCδ or JAK to address whether these 
upstream kinases are affected by PECAM-1 deletion.  In addition, to our knowledge, there 
are no reports of PECAM-1-JAK association, although JAKs are known to bind to other 
transmembrane receptors. Specifically, JAKs are usually coupled to cytokine receptors such 
as the gp130 rector family and become activated in response to cytokine stimulation. It has 
been shown that STAT3 binds PECAM-1 in an ITIM-independent manner	  15. Thus, it is 
possible that the scaffolding role of PECAM-1 is important for facilitating the spatial 
localization of molecules important in activating STAT3. It would be feasible to address this 
hypothesis by using PECAM-1 truncation mutants and assaying STAT3 activity or assessing 
PECAM-1-STAT3 interaction via biochemical analysis. Alternatively, it is possible that JAKs 
bind to the cytoplasmic domain of PECAM-1 which would spatially restrict them to an area 
where shear stress-responsive kinases such as Src-family kinases are located.  
Interestingly, previous studies have shown interplay between JAK and the Src-family kinase 
Lyn, which act synergistically in mature red blood cells to promote maturation	  16.  
Understanding the relationship between JAK/STAT and PECAM-1 is a relevant 
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consideration, as it may help explain or identify novel transcriptional targets downstream of 
PECAM-1.  
As mentioned in the previous section, my preliminary studies suggest that shear 
stress influences NOSTRIN expression.  Currently, it is unclear whether the change in 
NOSTRIN expression by shear stress is STAT3-dependent. Interestingly, relatively little is 
known about STAT3 function in ECs, and in particular, its regulation/activation by shear 
stress. The majority of work investigating STAT3 activation and transcriptional regulation 
has been done in the context of cytokine signaling and cancer.  Some studies have been 
done to address the relationship between shear stress and STAT3 signaling. However, 
differences in methodology make conclusions from these experiments unclear	  12,	  17.  One 
commonality is that shear stress appears to stimulate a transient increase in Ser727 and a 
decrease in Tyr705 phosphorylation, and phosphorylation of both residues is reduced after 
8h of shear.  My preliminary studies suggest an increase in NOSTRIN expression after 4hrs 
of shear.  Therefore, a more stringent time course of STAT3 phosphorylation by shear 
should be conducted to gain insight into the relationship between these events.  However, 
these data may also implicate a more direct role for Src in STAT3 phosphorylation, since it 
activated by shear stress and thought to play a role in STAT activation.   
 
CHAPTER III: A MECHANOSENSOR MEDIATES CROSSTALK BETWEEN 
ENDOTHELIAL CELLS AND CARDIOMYOCYTES TO REGULATE CARDIAC FUNCTION 
 
Previous work from our lab has suggested that PECAM-1 is important for mediating 
signaling between ECs and underlying cell types such as VSMCs	  5.  Given that the heart is 
composed of a significant proportion of ECs, which outnumber CMs 3:1	  18, we hypothesized 
that the same might be true in the heart.  In Chapter III I describe a novel role for PECAM-1 
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in regulating EC-CM crosstalk which affects cardiac function.  Our results were very 
intriguing and led us to ask additional questions regarding the complexity of this crosstalk.  
 
Shear stress signaling in the heart 
Due to its role as a flow sensor, we hypothesized that the defects in function 
observed in the PECAM-1-/- animals were due to impaired flow signaling. Although a role for 
shear stress has been shown during cardiac development in zebrafish and other model 
systems	  19,	  20, it is unclear how shear stress influences cardiac function in adult animals.  
Flow patterns generated in the heart are dynamic and varied depending on location.  
Therefore, ECs within the heart are exposed to different types of shear stress. For instance, 
endocardial ECs experience the filling and emptying of the ventricular chambers with every 
cardiac cycle, whereas the myocardial ECs encounter highly pulsatile flow, as the myocytes 
squeeze these vessels during contraction.    
To investigate the effect that shear stress has on the heart, one needs a model in 
which blood flow is manipulated with minimal effects on oxygen and nutrient delivery to the 
myocardium. One method is transverse aortic constriction (TAC).  In this model, partial 
ligation of the aorta increases the hemodynamic (shear) stress on the heart, in the ventricles 
and the myocapillaries.  The characteristic response to the increased stress is the 
development of cardiac hypertrophy.  The contribution of the endothelium to the 
development of hypertrophy is not well understood.  Using the PECAM-1-/- mice, we 
observed impaired remodeling and decreased activation of cardiac stress-responsive 
pathways.  This suggests that PECAM-1 is capable of detecting changes in shear stress 
that are important for cardiac hypertrophy. This finding is particularly intriguing, as the 
pathway(s) that initiate compensatory remodeling are poorly characterized.  It has previously 
been shown that CMs are able to detect changes in the hemodynamic environment which 
manifests as increased stress on the sarcomere. The muscle-specific protein muscle LIM 
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protein (MLP) is thought to function as a CM-specific mechanosensor	  21,	  22.  As changes in 
the hemodynamic environment also affect the CMs, it is possible that CM-specific pathways, 
such as MLP signaling may contribute to the minimal remodeling observed in the  
PECAM-1-/- mice after TAC (Figure 3.3).  
I have shown that impaired NRG-1-ErbB signaling within the heart contributes to the 
cardiac dysfunction observed in the PECAM-1-/- animals.  However, I have not shown 
whether this is due to an inability to regulate NRG-1 signaling in response to shear stress.  
Interestingly, previous studies have shown that one component of this pathway, the 
production of reactive oxygen species (ROS), is shear responsive.  Therefore, if shear-
induced ROS production is impaired in the PECAM-1-/- ECs, it would not be surprising that 
these cells have reduced NRG1 release.  We can address this question by subjecting 
PECAM-1 expressing and knockout ECs to shear stress using our in vitro flow system and 
measure subsequent NRG1 release.  An important consideration for these experiments is 
the type of flow that is experienced by the ECs in the complex environment of the heart.  
Our system allows manipulation of flow patterns allowing us to mimic the flow experienced 
by the myocapillary ECs, as well as the endocardial ECs.  
 
Which endothelial cells are important for regulating cardiac function? 
The work presented in Chapter III further strengthens the importance of EC-CM 
crosstalk in regulating cardiac function.  However, it does not address which population of 
ECs within the heart is required to regulate crosstalk.  There are three major populations of 
ECs within the heart: coronary, myocapillary, and endocardial.  Coronary ECs line the 
coronary blood vessels, which are superficial vessels that run along the surface of the heart.  
These vessels supply the cardiac muscle with oxygen-rich blood.  Despite this essential 
function, their contribution to EC-CM crosstalk is minimal.  These cells are anatomically 
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remote from the cardiomyocytes, thereby preventing the diffusion of important signaling 
molecules to underlying CMs.  
The myocapillary ECs, which surround each cardiomyocyte, and the endocardial 
ECs, which line the ventricular chambers, are in close proximity to the underlying 
cardiomyocytes.  These distances range from ~1µm for myocapillary ECs to 10-50µm for 
endocardial ECs	  18.  Myocapillary ECs and endocardial ECs differ in a number of ways, 
including cell morphology, type of cell junctions, and PECAM-1 distribution. Evidence for the 
latter comes from immunofluorescent localization of PECAM-1 in cardiac tissue sections.  In 
endocardial ECs, PECAM-1 is found primarily at border zones where ECs overlap	  23.  
Conversely, PECAM-1 staining in myocapillary ECs is observed diffusely over the cell 
surface	  18.  One could imagine that the differential localization of PECAM-1 in these cell 
populations could have profound effects on cell crosstalk and signaling. We know that 
PECAM-1 forms homophilic interactions with PECAM-1 on adjacent cells	  	  24 and that this 
interface is important for mediating a subset of signaling events.  However, it is unclear 
whether these interactions are important for regulating NRG1 release from ECs and more 
broadly, mediating signaling within the heart. 
To address which cardiac EC population is important for NRG1 signaling and 
elevated ErbB activation, I have performed preliminary experiments using cardiac tissue 
sections.  The sections were stained with antibodies against phosphorylated ErbB2/4 and 
imaged using confocal microscopy.  Unfortunately, images taken of the tissues were difficult 
to interpret due to challenges with staining, which we attribute to poor quality reagents.  It 
may be worthwhile to repeat this experiment using other available antibodies, as spatial 
differences in ErbB activation could be revealed.  A second method to establish the relevant 
EC signaling population would be to remove one population of ECs from the heart and 
assay cardiac function ex vivo.  It is extremely difficult to remove the myocapillary ECs, but 
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previous studies have denuded the endocardial ECs to assess their role in regulating 
cardiac function	  25.  One might hypothesize that if NRG1/ErbB signaling were elevated in 
endocardial ECs, removal of this layer of cells would reverse the systolic and diastolic 
dysfunction present in the PECAM-1-/- mouse. If the phenotype persists, these data would 
suggest that the myocapillary ECs might be important for mediating NRG-1 release.  
However, it is likely that the endocardial and myocapillary ECs play distinct roles in cellular 
crosstalk, and therefore, both contribute to cardiac function.  
 
INTEGRATING IN VITRO AND IN VIVO RESEARCH 
 
Although Chapter II and III seem disparate at first glance, it has become obvious, as 
both have progressed that they are more related than initially thought.  Several common 
themes are present in this dissertation, including the balance of signaling molecules and the 
interplay between pathways.  The aim of this section is to integrate these ideas and discuss 
them in the larger context of cardiovascular biology.  
 
Balance of signaling 
 In 1865, Claude Bernard first published the idea of milieu interieur, now referred to 
as homeostasis.  This concept describes the adaptations in behavior or signaling that 
maintain a constant condition, for example temperature. Homeostasis is an incredibly 
dynamic process and requires the presence of compensatory mechanisms to maintain 
values within a normal range.  The work presented in this thesis highlights the requirement 
for a balance of signaling molecules to maintain normal cardiovascular physiology. Central 
to both stories is the misregulaton of signaling molecules that are important for cellular 
crosstalk. In Chapter II, we observed increased NO production from the PE-KO cells, as well 
as in the plasma of PECAM-1-/- mice, and in Chapter III, we show increased NRG1-ErbB2 
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signaling in the PECAM-1-/- hearts.  In both cases, homeostasis must be maintained by the 
activation of compensatory mechanisms, which currently remain unknown.  However, we 
have identified several interesting possibilities, particularly in vivo. 
 
Contribution of alternative signaling pathways   
Studies in the 1980s by Furchgott and Zawadski demonstrated that ECs release 
compounds that affect vasomotricity (tone) of the surrounding VSMCs	  26.  The compound, 
initially termed endothelium derived relaxing factor, was later identified as NO	  27.  Their 
observations expanded the evolving role of ECs in vascular biology and revealed the 
possibility that ECs could play an important role in cell crosstalk.  Accordingly, more than a 
decade after the discovery of NO, studies determined that ECs could also influence cardiac 
contractility	  28,	  29.  This occurs through signaling molecules such as VEGF, ET-1, 
prostaglandins, NO, and NRG-1	  30. Although my work demonstrates that PECAM-1 is 
important for NO and NRG-1 release, it is highly likely that it also facilitates the production 
and/or release of additional signaling molecules. 
Blood vessel tone is a dynamically regulated process, consisting of changes in 
vasodilation (widening of the blood vessel) and vasoconstriction (narrowing of the blood 
vessel).  As discussed previously, NO participates in vasodilation, increasing perfusion of 
target tissues.  We found that PECAM-1-/- mice have increased plasma NO that may 
contribute to a decrease in blood pressure.  However, when we measure MAP in these 
animals, it is identical to wild-type controls.  These results suggest upregulation of 
vasoconstrictor signaling, such as increased expression of endothelin-1 (ET-1), in these 
mice.  It would be possible to test this hypothesis both in vitro and in vivo by measuring 
plasma ET-1 levels or ET-1 mRNA expression in ECs. One might also expect that 
components of the endothelin signaling pathway may also be upregulated such as 
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endothelin receptors, ETA on VSMCs and ETB on ECs.  An interesting experiment would be 
to treat isolated arterioles with endothelin and measure the contractile response with the 
expectation that the PECAM-1-/- vessels are more responsive (exhibit increased contractility) 
to ET-1 treatment. 
An interesting observation in the isolated cardiomyocyte studies led us to 
hypothesize a role for an alternative mechanism.  We noticed that PECAM-1-/- CMs were 
more responsive to isoproterenol stimulation than WT CMs.  Isoproterenol is a β-adrenergic 
agonist that is structurally similar to adrenaline.  Therefore, the compound stimulates β-
adrenergic receptors in the heart to increase heart rate and contractility.  One hypothesis for 
the increased responsiveness to isoproterenol in the PECAM-1-/- CMs is increased 
expression/activity of the adrenergic signaling pathway to compensate for higher muscarinic 
activity. It is well accepted that muscarinic and adrenergic signaling function to maintain 
normal cardiac function. Thus NO and NRG1 signaling have been shown to converge at the 
level of muscarinic signaling	  31, I hypothesize that increased input from the adrenergic 
pathway may be a compensatory mechanism for the depressed heart function.  
Regulation of adrenergic signaling is a complex process, involving the activity of 
downstream kinases such as G protein-coupled receptor kinase-2 (GRK2) as well as G-
proteins and β-arrestins.  Ligand binding to β-adrenergic receptors (βAR) leads to a 
conformational change in the receptor, facilitating its phosphorylation by GRK2, leading to 
receptor desensitization and internalization	  32.  Interestingly, adrenergic signaling is relevant 
in heart failure; decreased adrenergic signaling is observed in patients with congestive heart 
failure	  33References.   Furthermore, either peptide-mediated inhibition or genetic ablation of 
GRK2 can prevent the progression to heart failure	  34,	  35.  Because we have increased 
responsiveness to adrenergic stimulation, it is possible that levels of GRK2 are reduced in 
the PECAM-1-/- hearts.  Furthermore, there may be reduced levels of β-arrestins in CMs of 
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PECAM-1-/- mice.  These questions can be answered by measuring changes in gene and/or 
protein expression of these components.   
 
The signaling relationship between PECAM-1 and eNOS/NO in the heart 
While ET-1 signaling, among other pathway, may contribute to the phenotype of the 
PECAM-1-/- hearts, there is compelling evidence that eNOS/NO signaling may predominate. 
In Chapter II I show that PECAM-1 regulates eNOS and NO release.  Interestingly, there is 
a large body of literature implicating a role for NO in regulating cardiac contractility	  36.  In 
fact, it has been demonstrated that high levels of NO reduce contractility (negative inotropy), 
whereas low levels of NO increase contractility (positive inotropy)	  36.  We have measured 
cGMP from WT and PECAM-1-/- hearts as an indirect measure of NO production. Our 
preliminary data suggest that there is increased cGMP in the PECAM-1-/- hearts.  This 
correlates with my observations from PECAM-1-/- plasma and may indicate that contractility 
may be affected on two levels: one, through elevated NRG1/ErbB signaling and two, 
through elevated NO production.   
To address the possibility that PECAM-1-eNOS signaling is important in regulating 
cardiac function, we have generated a PECAM-1-/-/eNOS-/- mouse.  Preliminary 
characterization of this mouse revealed a markedly different phenotype from the PECAM-1-/- 
mouse.  These mice have reduced litter sizes and birthrates compared to either the 
PECAM-1-/- or eNOS-/- animals. Interestingly, the mice that survive develop significant 
hypertrophic cardiomyopathy as early as 4 weeks, as determined by conscious 
echocardiography. The hypertrophy is likely not due to high blood pressure, as the mean 
arterial pressure (MAP) in the PECAM-1-/-/eNOS-/- mice is only slightly increased above that 
of the PECAM-1-/- and significantly less than the eNOS-/-. Further characterization of these 
animals is currently under investigation in the lab.  
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Implications for cardiovascular biology 
The work presented in this thesis has broad implications for cardiovascular biology, 
both on the cellular and organ/animal level. Both PECAM-1 and eNOS are promiscuous 
proteins involved in many EC processes and signaling pathways.  By further characterizing 
their functions, we will gain a better understanding of EC function as a whole.  In addition to 
elucidating a role for PECAM-1 in the regulation of eNOS activity, the work in Chapter II also 
provides a clearer picture of eNOS regulation.  Endothelial dysfunction is characterized by 
misregulated eNOS/NO production, and its role in the progression of diseases like 
atherosclerosis is well documented.  Therefore, understanding the regulation of eNOS is 
central to the development of new targets for manipulating the health of the vessel.   
In Chapter III, we demonstrate the importance of PECAM-1, an endothelial protein, in 
directing cellular crosstalk and subsequent cardiac function.  Despite the appreciation that 
ECs modify heart function, the specific role of these cells remains poorly defined.  The 
contribution of CMs to cardiac function is well established, as are the intracellular 
components that regulate their function. Genetic mutations in both cytoskeletal anchoring 
proteins and sarcolemma proteins can lead to the development of DCM.  This includes the 
proteins titin	  37, which accounts for 25% of familial and 18% of sporadic DCM, cardiac 
myosin binding protein (MYBPC3)	  38, and laminin A/C	  39 among others.  Importantly, a large 
percent of DCM cases are idiopathic.  This population of disease may represent defects in 
cell-cell communication whose signaling pathways are poorly characterized.  More 
importantly, our work strengthens previous observations implicating the vasculature as a 
critical regulator of cardiac function. 
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